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Acute Respiratory Distress Syndrome in Persons with Tickborne
Relapsing Fever — Three States, 2004–2005
Tickborne relapsing fever (TBRF) is a bacterial illness
caused by certain species of Borrelia and transmitted through
brief and painless bites from Ornithodoros ticks (1,2).
Illness usually is characterized by intermittent periods of
fever, fatigue, and muscle aches. In April 2005, CDC
received reports of two cases of severe TBRF associated with
acute respiratory distress syndrome (ARDS) in residents of
California and Nevada. After a report describing these cases
was posted on CDC’s Epidemic Information Exchange (Epi-
X), health officials in Washington reported a third severe
case associated with ARDS. This report summarizes these
three cases and the results of the subsequent epidemiologic
investigations. The findings indicate that ARDS might oc-
cur more frequently in patients with TBRF than previously
recognized. Optimal management of TBRF requires both
prompt diagnosis and careful observation during the ini-
tial phases of treatment.
Case Reports
Nevada. On February 17, 2005, a previously healthy
woman aged 46 years from Washoe County, Nevada, had
onset of nonspecific leg pain, which progressed during the
next 24 hours to generalized myalgia. She visited a local
hospital emergency department (ED), where a viral syn-
drome was diagnosed. She was treated with intravenous (IV)
fluids and pain medication and discharged home. Two days
later, she returned to the ED with fever, chills, fatigue,
anorexia, nausea, and an episode of syncope. On arrival,
she was noted to be tachycardic (130 beats per minute
[bpm]), tachypneic (24 breaths per minute), and hypoten-
sive (systolic blood pressure: 89 mm Hg) with a tempera-
ture of 96.8°F (36.0°C). A physical examination was
otherwise unremarkable. Pulse oximetry on room air
indicated an oxygen saturation of 96%. Initial laboratory
testing revealed a white blood cell count (WBC) of 11.4 ×
103/µL, hemoglobin level of 13 g/dL, platelet count of 66
× 103/µL, and alanine aminotransferase (ALT) of 153 U/L.
A chest radiograph revealed a right middle lobe infiltrate,
consistent with community-acquired pneumonia.
She was treated with gatifloxacin and transferred to the
intensive care unit (ICU). Approximately 10 hours after
admission, she was intubated for worsening tachypnea (res-
piratory rate [RR]: 40 breaths per minute). Diffuse bilat-
eral infiltrates were noted on chest radiograph, and an
arterial blood gas sample yielded oxygenation of 53 mmHg
on 100% inspired oxygen. The patient’s antimicrobial treat-
ment was broadened to include vancomycin and doxycy-
cline. The next day, the treating physician was notified that
spirochetes were observed during examination of a blood
smear obtained when the patient was admitted; the smear
had been manually reviewed because of thrombocytopenia.
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The patient remained intubated for 12 days for what
was ultimately determined to be ARDS. During this time,
she was administered three additional antimicrobials
(ciprofloxacin, tobramycin, and ceftriaxone) and
drotrecogin-α.* She was discharged after 21 days and re-
covered completely. The causative organism was identified
as Borrelia hermsii by polymerase chain reaction (PCR) per-
formed on a whole blood sample and serologic testing of
convalescent-phase serum, both performed at CDC. Al-
though the patient did not recall receiving a tick bite, she
did report staying at a resort near South Lake Tahoe (an
area known to be highly endemic for TBRF) 5 days before
becoming ill.
California. On April 12, 2005, a previously healthy
woman aged 43 years from El Dorado County, California,
had onset of lethargy and myalgia. She went to a local hos-
pital ED on April 14 with fever, chills, headache, myalgia,
and dehydration. She was febrile (100.5°F [38.1°C]),
tachycardic (138 bpm), mildly tachypneic (16 breaths per
minute), and hypotensive (systolic blood pressure: 97 mm
Hg). A physical examination was otherwise unremarkable.
Pulse oximetry on room air indicated an oxygen saturation
of 97%. A chest radiograph was not obtained, but initial
blood tests indicated an elevated bilirubin level of 3.6 mg/
dL, aspartate aminotransferase (AST) of 93 U/L, and ALT
of 88 U/L. She was treated with acetaminophen and dis-
charged home with instructions to return for reevaluation
of blood tests the next day.
The patient returned the next day with headache, sweat-
ing, fatigue, and nausea. A physical examination revealed
rhonchi; a chest radiograph was obtained and read as nor-
mal. She was treated with IV fluids and IV ceftriaxone.
Within 1 hour of receiving antibiotics, her pulse increased
to 127 bpm, her systolic blood pressure decreased to 85
mm Hg, and pulse oximetry on room air indicated an oxy-
gen saturation of 95%. TBRF was diagnosed by observa-
tion of spirochetes in smears of peripheral blood (Figure).
The patient was treated with dopamine for hypotension
and doxycycline for TBRF and transferred to another medical
center. Shortly after arrival, a chest radiograph taken be-
cause of worsening respiratory distress demonstrated dif-
fuse bilateral infiltrates. The patient was intubated for
respiratory failure (RR: 44 breaths per minute; oxygen satu-
ration of 82% on 100% inspired oxygen via nonrebreather
mask) attributed to ARDS. Laboratory testing revealed a
WBC of 3.4 × 103/µL, hemoglobin level of 11.4 g/dL, and
* Drotrecogin-α (Xigris®) primarily is used to treat severe sepsis. The drug is a
recombinant form of human activated protein C that has antithrombocytic,
antiinflammatory, and profibrinolytic properties.
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platelet count of 19 × 103/µL. Platelets and fresh frozen
plasma were administered.
The patient remained intubated for 10 days, during which
she was administered four different antimicrobials (vanco-
mycin, piperacillin/tazobactam, metronidazole, and doxy-
cycline) and drotrecogin-a. She was discharged after 19 days
of hospitalization and eventually recovered from her illness.
A blood sample obtained early in illness and cultured at
CDC yielded B. hermsii. An environmental investigation
was conducted at her home, located 5 miles south of Lake
Tahoe and approximately 10 miles from the resort visited
by the Nevada patient. An engorged soft tick was found in
her bedroom, and removal of house siding revealed mul-
tiple rodent nests from which approximately 30 Ornithodoros
hermsi ticks were recovered.
Washington. A woman aged 40 years from King County,
Washington, visited a hospital ED on September 21, 2004,
with myalgia, arthralgia, nausea, vomiting, and headache.
She was treated with IV fluids, promethazine, and
hydrocodone. Hospital admission was recommended, but
she refused. After experiencing a syncopal episode at home,
she returned and was noted to be febrile (102ºF [38.9°C]),
hypotensive (systolic blood pressure: 100 mm Hg), mildly
tachycardic (107 bpm), and hypoxic (oxygen saturation:
92% on 4 L of oxygen). A physical examination was other-
wise unremarkable. Her chest radiograph revealed bilateral
lower lobe infiltrates. Initial laboratory studies indicated a
WBC of 9.5 x 103/µL, hematocrit of 33%, platelet count
of 49 x 103/µL, ALT of 192 U/L, and a D-dimer of 754.
She was admitted for presumed community-acquired pneu-
monia with sepsis and treated empirically with IV
cefuroxime and azithromycin. After receiving the cefuroxime,
she was transiently hypotensive and became somnolent. She
was intubated and transferred to the ICU with a diagnosis
of ARDS and worsening mental status.
Because of thrombocytopenia, a peripheral blood smear
was examined, revealing spirochetes diagnostic of TBRF.
Her transient hypotension was attributed to a Jarisch-
Herxheimer reaction (JHR).† She remained intubated for
3 days, was discharged home after 10 days, and eventually
recovered from her illness. The most likely site of exposure
was a forest cabin in Chelan County, Washington, where
she had slept approximately 11 days before illness onset.
On inspection, the cabin had evidence of rodent infesta-
tion; however, attempts to trap ticks and rodents were
unsuccessful.
Epidemiologic Investigations
To determine the frequency of ARDS among patients with
TBRF acquired in the South Lake Tahoe area, case-report
forms for all TBRF cases reported to Nevada and California
state and local health departments during 1995–2004 were
reviewed. Additionally, cases were ascertained by 1) a com-
puterized search of discharge records from Lake Tahoe area
hospitals where cases had been diagnosed; 2) interviews
with physicians and laboratorians from area hospitals and
private practices where cases had been diagnosed; and 3)
postings on Epi-X and the Emerging Infections Network.
Including the California and Nevada cases described in this
report, 65 cases of TBRF among persons who reported living
in or visiting the Lake Tahoe area during the usual incubation
period of 2–18 days before illness onset were ascertained. Thirty
(46%) were in patients who required hospitalization. Detailed
clinical information from medical records was available for 38
(58%) patients. Among these 38 patients, 16 (42%) experi-
enced one or more of the following complications: eight (21%),
JHR; six (16%), hypoxia; five (13%), elevated liver enzyme
levels; three (8%), arrhythmia or myocarditis; two (5%),
azotemia; and two (5%), ARDS.
TBRF cases in Washington state were similarly reviewed
by using all case reports submitted to the state health
department during 1996–2005. Including the single case
described in this report, 46 TBRF cases were reported in
Washington during 1996–2005, of which 37 (80%) were
in patients who required hospitalization. Comments on
case-report forms indicated that five (13%) patients required
care in an ICU, three (6%) had JHR, and three (6%) had
ARDS. All three ARDS cases occurred after 2001.
Reported by: FK Murphy, MD, S Parker, MD, Sierra Infectious Diseases,
Reno; D Stokich, M Murray, Washoe County District Health Dept;
V Fogelman, DVM, R Todd, DrPH, Nevada State Health Div. V Huber,
El Dorado County Environmental Management Dept; A Tabor,
N Deatherage, El Dorado County Public Health Dept; J Tucker, C Fritz,
† JHR is an acute exacerbation of symptoms, attributed to decreasing bacterial
numbers and a massive cytokine release, which can occur during initial treatment
of spirochetal infections (e.g., relapsing fever and syphilis) with an effective
antibiotic. Symptoms include hypotension, tachycardia, chills, rigors, diaphoresis,
and elevated body temperature (1).
FIGURE. Spirochete (noted by arrow) on peripheral blood smear
obtained from California patient (Giemsa stain)
Photo/CDC
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DVM, J Mohle-Boetani, MD, California Dept of Health Svcs. C Skilton,
MS, Public Health Seattle–King County, Washington. K Kugeler, MPH,
M Schriefer, PhD, P Mead, MD, Div of Vector-Borne Infectious Diseases,
National Center for Zoonotic, Vector-Borne, and Enteric Diseases; L Minicucci,
DVM, E Sergienko, MD, JE Staples, MD, C Wheeler, MD, EIS officers, CDC.
Editorial Note: Although TBRF is not a nationally notifi-
able disease, it is a reportable condition in 11 western states.
Each year, approximately 25 cases are reported to CDC, all
among residents of or visitors to western states where the
disease is endemic (CDC, unpublished data, 2007). Most
cases are caused by B. hermsii, which is transmitted to
humans through the bite of O. hermsi ticks (1,2). These
ticks typically feed for less than 30 minutes and usually at
night; consequently, most patients do not recall being bit-
ten. Rodents are vertebrate reservoirs for the disease, and
cabins or homes located at elevations of 2,000–7,000 feet
in coniferous forests are common exposure sites. Outbreaks
associated with such sites have been reported from Arizona,
California, Colorado, Montana, New Mexico, and
Washington (3–8).
Clinical symptoms of TBRF have included fever, head-
ache, myalgia, chills, and nausea. Without antimicrobial
treatment, patients typically experience multiple episodes
of febrile illness. Rarely reported complications include
uveitis, cranial nerve palsy, myocarditis, splenic rupture,
and JHR (1,2). Only one case of TBRF with ARDS has
been described previously (9), and this case occurred in a
woman who was pregnant and therefore more susceptible
to severe TBRF (10).
Results of this investigation indicate that ARDS might
occur more frequently in patients with TBRF than previ-
ously recognized and can occur in persons without predis-
posing conditions. All cases of TBRF-associated ARDS
identified in this review occurred after 2001, but further
surveillance will be needed to determine whether the risk
for ARDS in TBRF is increasing. Increases might be
related to changes in medical practice, use of newer anti-
microbials, or possibly the emergence of a more virulent
strain. All three cases described in this report occurred in
women, but no common medical history (e.g., menopausal
status, hormone replacement therapy, or oral contracep-
tive use) was identified. All three patients had received
antimicrobial treatment before onset of ARDS; however,
whether they had ARDS as a result of JHR or underlying
sepsis could not be determined.
The findings in this report are subject to at least two
limitations. First, cases were evaluated in only two
geographic areas; therefore, results might not be generaliz-
able to the endemic western states. Second, TBRF is not a
nationally notifiable disease, and each state has different
reporting requirements; therefore, case information is sub-
ject to underreporting and ascertainment bias. These meth-
odological differences might have affected the observed rates
of hospitalization and classification of ARDS.
Health-care professionals should report suspected TBRF
cases to local or state health departments, providing a thor-
ough clinical and exposure history and, as appropriate,
samples (i.e., serum or whole blood) for diagnostic testing.
The observation of spirochetes in a Wright- or Giemsa-
stained peripheral blood smear collected during a febrile
episode is considered diagnostic of TBRF and is not typical
of other spirochetal infections (1). Laboratory diagnosis also
can be made by culture, serology, or PCR of serum and
blood at certain reference laboratories.
TBRF can be prevented by minimizing rodent infesta-
tions in homes. Health officials in endemic areas should
consider educational measures that increase awareness of
potential exposures, demonstrate methods for
rodent proofing dwellings, and promote early recognition
of cases by health-care professionals (5). These measures
are especially important in mountainous resort areas that
serve numerous visitors.
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Streptococcus pneumoniae (pneumococcus) is a leading
cause of otitis, sinusitis, pneumonia, and meningitis world-
wide. Treatment of the most serious type of pneumococcal
infection, invasive pneumococcal disease (IPD),* is com-
plicated by antimicrobial resistance. Widespread introduc-
tion in 2000 of heptavalent pneumococcal conjugate
vaccine (PCV7) against serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F resulted in a decline in antimicrobial-
nonsusceptible IPD in the United States (1,2), including
in Massachusetts (3). However, development of antimicro-
bial resistance in serotypes not covered by PCV7 is a grow-
ing concern (1,4). In Massachusetts during 2001–2006,
IPD surveillance identified an increased number of cases in
children caused by pneumococcal serotypes (most notably
19A) not covered by PCV7 and an associated increase in
antimicrobial resistance among these isolates. This report
examines these trends and clinical characteristics of Massa-
chusetts patients with antimicrobial-nonsusceptible, non–
PCV7-type IPD. The findings indicated that, despite
increases in incidence of antimicrobial-nonsusceptible IPD,
overall rates of IPD remained stable during 2001–2006.
In addition, persons with IPD caused by antimicrobial-
nonsusceptible S. pneumoniae had clinical outcomes com-
parable to persons with IPD caused by antimicrobial-
susceptible serotypes. Although PCV7 is effective in prevent-
ing IPD, these results confirm that antimicrobial resistance
among serotypes not covered by PCV7 remains a concern.
On October 1, 2001, the Massachusetts Department of
Public Health and the Section of Pediatric Infectious Diseases
at Boston University Medical Center initiated statewide
laboratory- and population-based surveillance for IPD among
children.† For this report, cases of IPD were defined by
isolation of pneumococcus from a normally sterile body
site (e.g., blood or cerebrospinal, pleural, or joint fluid) in
a Massachusetts resident aged <18 years during October
1, 2001–September 30, 2006. Demographic and clinical
data were obtained from telephone interviews with primary-
care providers or adult caregivers. PCV7 vaccination rates
were estimated using CDC’s National Immunization Survey.§
Serotyping was performed at Boston University Medical
Center, using the Quellung reaction with pneumococcal
antisera. Susceptibility to five antimicrobials often used in
pediatric patients (i.e., amoxicillin, penicillin, ceftriaxone,
azithromycin, and trimethoprim-sulfamethoxazole) was
determined by E-test (epsilometer test, an agar diffusion
method), and interpretations were based on Clinical and
Laboratory Standards Institute 2007 guidelines (5). For
each antimicrobial agent tested, isolates with either inter-
mediate-level or high-level antimicrobial resistance were
considered nonsusceptible to the antimicrobial agent un-
less otherwise indicated. Population denominators were
obtained from 2000–2005 census figures. Mantel-Haenszel
chi-square test for trend was used to identify changes in
serotype distribution or antimicrobial resistance over time.
Chi-square or Fisher’s exact tests of proportions were used
to compare risk factors and clinical characteristics of dis-
ease. Because IPD surveillance did not begin until after
introduction of PCV7, no data on pre-PCV7 susceptibility
were available for comparison.
PCV7 was administered widely to Massachusetts children
beginning in 2000. Although PCV7 shortages occurred
nationwide, shortages were moderate in Massachusetts. By
2005, approximately 95% of Massachusetts children
aged 19–35 months had received >3 PCV7 doses.
During October 2001–September 2006, surveillance
identified 467 cases of IPD in Massachusetts residents aged
<18 years. Throughout this period, annual IPD incidence
rates were stable, ranging from 15.9 to 18.6 per 100,000
children aged <5 years (Figure 1); rates were approximately
70% lower than the pre-PCV7 annual IPD incidence of
56.9 per 100,000 children aged <5 years documented in
* IPD is defined by isolation of S. pneumoniae from a normally sterile body site
(e.g., blood or cerebrospinal, pleural, or joint fluid).
† Partial support for the IPD surveillance was provided by Wyeth as part of the
investigator-initiated proposal.
§ Information available at http://www.cdc.gov/vaccines/stats-surv/imz-coverage.
htm#nis.
FIGURE 1. Incidence rate* for invasive pneumococcal disease
among persons aged <5 years and aged 5 to <18 years —
Massachusetts, October 1, 2001–September 30, 2006
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surveillance during 1990–1991 (6). A total of 353 isolates
(76%) from 467 cases were available for serotyping. Dur-
ing 2001–2006, a total of 94 (27%) isolates were serotype
19A. During that period, the number and percentage of
IPD cases caused by serotype 19A increased from six (10%
of all cases) during 2001–2002 to 33 (41%) during 2005–
2006 (p<0.01) (Figure 2). No significant changes were noted
in the proportions of IPD caused by other PCV7 or PCV7-
related serotypes or by non-PCV7 serogroups (Figure 2).
Because 19A was the most common serotype isolated dur-
ing 2005–2006, the antimicrobial susceptibility of 19A iso-
lates was examined further (Table). The majority of 19A
isolates were nonsusceptible to penicillin. During 2001–
2006, significant increases were noted in the proportion of
19A isolates that were nonsusceptible to amoxicillin (mini-
mum inhibitory concentration [MIC] >2 µg/mL),
ceftriaxone (MIC >0.5 µg/mL), or three or more classes of
antimicrobials (Table). Fourteen (15%) of 94 isolates of
19A were highly resistant to ceftriaxone (MIC >2 µg/ml), a
first-line antimicrobial used for empiric bacterial meningi-
tis treatment. No significant trends in the antimicrobial
resistance of non-19A isolates were noted.
To describe the clinical features of and identify risk fac-
tors for infection with ceftriaxone-nonsusceptible serotype
19A, demographic and clinical characteristics of the 14
patients with highly ceftriaxone-resistant 19A IPD were
compared with those of 73 patients with ceftriaxone-
susceptible 19A IPD and 237 patients with ceftriaxone-
susceptible non-19A IPD. The results indicated that
patients with highly ceftriaxone-resistant 19A disease did
not differ from the other groups with regard to established
risk factors for antimicrobial-nonsusceptible pneumococ-
cal disease, including age, sex, race/ethnicity, geographic
region, degree of household crowding, or day care expo-
sure. Underlying medical conditions that might predispose
to IPD (e.g., sickle cell disease or congenital or acquired
immune deficiencies) were not significantly more common
among patients with highly ceftriaxone-resistant 19A IPD
(three of 14 [21%]) than among patients in the ceftriaxone-
susceptible 19A group (nine of 73 [12%]) or the non-19A
group (33 of 237 [14%]). In addition, no significant dif-
ferences among the three groups were detected in the pro-
portion of patients with meningitis, pneumonia, or
bacteremia without focus, case-fatality ratios, rates of hos-
pitalization (79% versus 68% and 59%, respectively), or
longer hospital stay (64% with >4 days versus 40% and
51%, respectively).
Reported by: KK Hsu, MD, JE Kellenberg, MPH, SI Pelton, MD, Boston
Univ Medical Center; DS Friedman, PhD, Massachusetts Dept of Public
Health. MR Moore, MD, Div of Bacterial Diseases, National Center for
Immunization and Respiratory Diseases; HT Jordan, MD, EIS Officer, CDC.
Editorial Note: During 2001–2006, Massachusetts sur-
veillance identified an increase in the proportion of child-
hood IPD cases caused by serotype 19A and increasing
resistance of 19A isolates to commonly used antimicrobi-
als. Increases in the proportion of IPD caused by pneumo-
coccal serotypes not covered by PCV7 have been reported
previously (1,4,7,8). In Massachusetts and in other states,
serotype 19A has emerged as the most common cause of
IPD, and the proportion of 19A isolates that are
nonsusceptible to commonly used antimicrobials is greater
than the proportion for other serotypes (1,4). As a member
of the same serogroup as the PCV7-type 19F, serotype 19A
is considered a PCV7-related serotype. However, PCV7-
induced antibodies to 19F are not active against serotype
19A (9).
FIGURE 2. Number of cases of invasive pneumococcal disease
among persons aged <18 years, by PCV7* status of  Streptococcus
pneumoniae serotypes — Massachusetts, October 1, 2001–
September 30, 2006
* Heptavalent pneumococcal conjugate vaccine.
†
PCV7-related serotypes are in the same serogroups as PCV7 vaccine
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F).
§
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Concern exists that emergence of antimicrobial-
nonsusceptible non–PCV7-type IPD could erode the
success of PCV7 against pneumococcal infections. The lim-
ited number of 19A cases restricted the ability of this study
to identify risk factors or characteristic clinical features of
antimicrobial-nonsusceptible 19A disease. However, the
study found no evidence that infections caused by antimi-
crobial-nonsusceptible serotype 19A had different clinical
syndromes or outcomes than infections caused by antimi-
crobial-susceptible 19A. Despite the lack of continuous sur-
veillance data before PCV7 introduction, the overall stability
of IPD incidence in Massachusetts during the study period
indicates that the decline in IPD resulting from PCV7 in-
troduction is being maintained (3,6). Furthermore, antimi-
crobial-nonsusceptible infections have not negated the
positive impact of PCV7. Accordingly, vaccination with PCV7
remains a priority in Massachusetts.
Nonetheless, the emergence of antimicrobial-nonsusceptible
non–PCV7-type IPD is of concern. Continued surveillance
for IPD in Massachusetts will provide data on the clinical
impact of antimicrobial-nonsusceptible 19A infection and will
be useful in development and monitoring of new pneumo-
coccal vaccines.
The findings in this report support the continued empiric
use of combination therapy with vancomycin and cefotaxime
or ceftriaxone (the antimicrobials of choice to treat
nonsusceptible pneumococci) for children with bacterial
meningitis caused by, or possibly caused by, S. pneumoniae,
and for critically ill children with nonmeningeal IPD (10).
Antimicrobial-resistance data obtained through surveillance
will continue to guide empiric treatment regimens for IPD
in Massachusetts and provide data that can be used to tai-
lor treatment recommendations to state-specific resistance
patterns. State-based surveillance also will help detect trends
in the emergence of nonsusceptible non-PCV7 IPD.
The recent development of polymerase chain reaction
(PCR)-based serotyping provides the opportunity for state
public health laboratories and academic partners to iden-
tify IPD isolates by serotype. Serotyping based on the
Quellung reaction requires expensive reagents and substan-
tial training and experience to perform reliably. In con-
trast, PCR-based serotyping can be performed using
commercially available reagents and equipment and tech-
nical expertise already available in most state public health
laboratories.¶ If applied in other states, these techniques
might increase understanding of IPD trends that have oc-
curred nationally since introduction of PCV7.
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Update: Prevention of Hepatitis A
After Exposure to Hepatitis A Virus
and in International Travelers.
Updated Recommendations
of the Advisory Committee
on Immunization Practices (ACIP)
In 1995, highly effective inactivated hepatitis A vaccines
were first licensed in the United States for preexposure pro-
phylaxis against hepatitis A virus (HAV) among persons aged
>2 years. In 2005, vaccine manufacturers received Food and
Drug Administration approval for use of the vaccines in chil-
dren aged 12–23 months (1).
The Advisory Committee on Immunization Practices
(ACIP) issued recommendations for preexposure use of hepa-
titis A vaccine in 1996, 1999, and 2006 (1). Currently, ACIP
recommends hepatitis A vaccination of all children at age
12–23 months, catch-up vaccination of older children in
selected areas, and vaccination of persons at increased risk for
hepatitis A (e.g., travelers to endemic areas, users of illicit drugs,
or men who have sex with men) (1).
For decades, immune globulin (IG) has been recommended
for prophylaxis after exposure to HAV (1). IG also has been
recommended in addition to hepatitis A vaccine for
preexposure prophylaxis for travelers to countries with high
or intermediate hepatitis A endemicity who are scheduled to
depart <4 weeks after receiving the initial vaccine dose. This
report details updated recommendations, made by ACIP
in June 2007, for prevention of hepatitis A after exposure
to HAV and in departing international travelers (Box) and
incorporates existing ACIP recommendations for preven-
tion of hepatitis A (1).
Rationale and Methods for Updated
Recommendations
When administered within 2 weeks of last exposure, IG
is 80%–90% effective in preventing clinical hepatitis A.
Despite previously available limited data suggesting that
hepatitis A vaccine might be efficacious when administered
after exposure (2), in the absence of an appropriately
BOX. Summary of updated recommendations for prevention
of hepatitis A after exposure to hepatitis A virus (HAV) and in
departing international travelers
Postexposure prophylaxis
Persons who recently have been exposed to HAV and
who previously have not received hepatitis A vaccine should
be administered a single dose of single-antigen hepatitis A
vaccine or immune globulin (IG) (0.02 mL/kg) as soon
as possible.
• For healthy persons aged 12 months–40 years, single-
antigen hepatitis A vaccine at the age-appropriate dose
is preferred.
• For persons aged >40 years, IG is preferred; vaccine can
be used if IG cannot be obtained.
• For children aged <12 months, immunocompromised
persons, persons who have had chronic liver disease
diagnosed, and persons for whom vaccine is contrain-
dicated, IG should be used.
International travel
All susceptible persons traveling to or working in coun-
tries that have high or intermediate hepatitis A endemic-
ity should be vaccinated or receive IG before departure.
Hepatitis A vaccine at the age-appropriate dose is pre-
ferred to IG. The first dose of hepatitis A vaccine should
be administered as soon as travel is considered.
• One dose of single-antigen hepatitis A vaccine adminis-
tered at any time before departure can provide adequate
protection for most healthy persons.
• Older adults, immunocompromised persons, and per-
sons with chronic liver disease or other chronic medical
conditions planning to depart to an area in <2 weeks
should receive the initial dose of vaccine and also simul-
taneously can be administered IG (0.02 mL/kg) at a
separate anatomic injection site.
• Travelers who elect not to receive vaccine, are aged
<12 months, or are allergic to a vaccine component
should receive a single dose of IG (0.02 mL/kg), which
provides effective protection for up to 3 months.
NOTE: Previous recommendations remain unchanged regarding 1) settings
in which postexposure prophylaxis is indicated, and 2) timing of
administration of postexposure prophylaxis.
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designed clinical trial comparing the postexposure efficacy
of vaccine with that of IG, ACIP continued to recommend
IG exclusively for postexposure use (1). Hepatitis A vac-
cine, if recommended for other reasons, could be given at
the same time. ACIP was prompted to revisit these recom-
mendations when findings became available from a ran-
domized, double-blind noninferiority clinical trial
comparing the efficacy of hepatitis A vaccine and IG after
exposure to HAV (3).
The results of this clinical trial were presented to ACIP
at its February 2007 meeting. During April–May 2007,
the ACIP Hepatitis Vaccines Workgroup considered these
results in a series of teleconferences. During these telecon-
ferences, the workgroup also considered the experiences of
other countries (e.g., Canada and the United Kingdom)
where hepatitis A vaccine has been recommended for
postexposure use for >5 years and reviewed data on the
immunogenicity of hepatitis A vaccine, the risk for HAV
transmission in various settings, and factors known to
affect the severity of hepatitis A. Additionally, the workgroup
took into account potential advantages of vaccine, recog-
nized disadvantages of IG, and relevance of these data to
existing recommendations for use of hepatitis A vaccine and
IG in international travelers departing <4 weeks after
receiving the first dose of hepatitis A vaccine. The workgroup
also considered the likelihood that no additional
postexposure efficacy data would become available, because
of the difficulties of conducting postexposure efficacy studies
of IG and vaccine.
On the basis of this evidence and the expert opinions of
workgroup members, other scientists, and feedback from ACIP
partner organizations, the ACIP Hepatitis Vaccines Workgroup
drafted a revision of the hepatitis A postexposure prophylaxis
and travel recommendations. These updated recommenda-
tions were deliberated and approved by ACIP at the June 2007
meeting.
I. Prevention of Hepatitis A After Exposure
to HAV
Efficacy of hepatitis A vaccine versus IG. The clinical trial
comparing hepatitis A vaccine with IG was conducted among
1,090 persons aged 2–40 years who were contacts of hepatitis
A cases and susceptible to HAV infection. The trial compared
the efficacy of hepatitis A vaccine and IG in preventing
laboratory-confirmed symptomatic hepatitis A (i.e., the pri-
mary outcome) when administered <14 days after exposure
to HAV (3). The primary outcome occurred among 25 (4.4%)
of 568 recipients of hepatitis A vaccine and 17 (3.3%) of
522 IG recipients (relative risk: 1.35; 95% confidence
interval [CI] = 0.70–2.67); the prespecified statistical
criterion for noninferiority was met. The low frequency of
study endpoints among IG and vaccine recipients indicated
that both interventions provided good protection. The risk
for hepatitis A in the vaccine group was never more than
1.5 percentage points greater than that for the IG group
for the primary outcome or any secondary study endpoint.
Assuming IG is 90% efficacious, the point estimate for
hepatitis A vaccine efficacy relative to IG in preventing clini-
cal hepatitis A was 86% (CI = 73%–93%) (3). This clini-
cal trial suggested that the performance of vaccine, when
administered <14 days after exposure, approaches that of
IG in healthy children and adults aged <40 years. How-
ever, these findings might not be generalizable to all popu-
lations and settings. In contrast, years of experience have
demonstrated that IG performs well as postexposure pro-
phylaxis in all populations and settings.
Advantages of hepatitis A vaccine. The ability to use
hepatitis A vaccine for postexposure prophylaxis provides
numerous public health advantages, including the induc-
tion of active immunity and longer protection, greater ease
of administration, higher acceptability and availability, and
a cost per dose that is similar to IG. Also, the greater avail-
ability and ease of administration of hepatitis A vaccine
might increase the number of persons at risk for infection
who receive postexposure prophylaxis.
Risk for HAV transmission in various settings. The risk
for transmission of HAV is influenced by host and environ-
mental factors and varies considerably in different settings.
For example, without postexposure prophylaxis, secondary
attack rates of 15%–30% have been reported in households,
with higher rates of transmission occurring from infected
young children than from infected adolescents and adults
(4–6). In contrast, attack rates among patrons of food service
establishments who have been exposed to HAV-infected food
handlers generally are low (7). Indeed, most food handlers
with hepatitis A do not transmit HAV to exposed consum-
ers or restaurant patrons (7). Given the wide range of HAV
transmission risks in various settings for which postexposure
prophylaxis is recommended, magnitude of risk in each situ-
ation is an important factor in determining whether to use
IG or vaccine.
Factors affecting clinical manifestations of hepatitis A.
Older persons and persons with chronic liver disease are more
likely to have severe manifestations of hepatitis A. Among
older children and adults, infection typically is symptom-
atic, with jaundice occurring in >70% of patients (8). The
case-fatality rate among cases reported through national sur-
veillance reaches a high of 1.8% among persons aged >60
years, and fulminant hepatitis has been reported more fre-
quently among older patients with hepatitis A (9). Although
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not at increased risk for HAV infection, persons with chronic
liver disease also are at increased risk for fulminant hepati-
tis A (10). Because of the frequency of severe consequences,
preventing hepatitis A among exposed older persons and
persons with chronic liver disease is particularly vital. The
performance of hepatitis A vaccine as postexposure prophy-
laxis in these groups was not assessed in the recent clinical
trial and remains unknown. In contrast, IG has been rec-
ommended and used successfully for many years in these
groups and in the general population.
These recommendations replace previous ACIP recom-
mendations for postexposure prophylaxis with IG (1), in-
corporating new recommendations for use of single-antigen
hepatitis A vaccine and updated recommendations for use
of IG postexposure. These recommendations also incorpo-
rate and consolidate existing recommendations regarding
recommended settings for which postexposure prophylaxis
is indicated, including close personal contact with a person
with hepatitis A and selected circumstances in which hepa-
titis A is recognized in a food handler or in a child care
center (1). Also, the updated recommendations leave
unchanged the recommendation that postexposure prophy-
laxis (using vaccine or IG) should be administered as soon
as possible. No information exists regarding the efficacy of
IG or vaccine if administered >2 weeks after exposure (1).
The updated recommendations for use of hepatitis A vac-
cine alone for postexposure prophylaxis do not apply to
the combination hepatitis A/hepatitis B vaccine because
no data exist regarding the performance of the combina-
tion vaccine for prophylaxis after exposure to HAV. The
concentration of HAV antigen in the currently available
combination vaccine formulation is half that included in
the single-antigen vaccine available from the same manu-
facturer (1).
Recommendations for postexposure prophylaxis with IG
or hepatitis A vaccine. Persons who recently have been
exposed to HAV and who previously have not received hepa-
titis A vaccine should be administered a single dose of single-
antigen vaccine or IG (0.02 mL/kg) as soon as possible.
Information about the relative efficacy of vaccine compared
with IG postexposure is limited, and no data are available for
persons aged >40 years or those with underlying medical con-
ditions. Therefore, decisions to use vaccine or IG should
take into account patient characteristics associated with
more severe manifestations of hepatitis A, including older
age and chronic liver disease.
For healthy persons aged 12 months–40 years, single-
antigen hepatitis A vaccine at the age-appropriate dose is
preferred to IG because of vaccine advantages that include
long-term protection and ease of administration. For
persons aged >40 years, IG is preferred because of the
absence of information regarding vaccine performance and
the more severe manifestations of hepatitis A in this age
group; vaccine can be used if IG cannot be obtained. The
magnitude of the risk for HAV transmission from the expo-
sure should be considered in decisions to use IG or vaccine.
IG should be used for children aged <12 months,
immunocompromised persons, persons who have had
chronic liver disease diagnosed, and persons for whom
vaccine is contraindicated.
Persons administered IG for whom hepatitis A vaccine
also is recommended for other reasons should receive a dose
of vaccine simultaneously with IG. For persons who receive
vaccine, the second dose should be administered according
to the licensed schedule to complete the series. The effi-
cacy of IG or vaccine when administered >2 weeks after
exposure has not been established.
Close personal contact. Hepatitis A vaccine or IG should
be administered to all previously unvaccinated household
and sexual contacts of persons with serologically confirmed
hepatitis A. In addition, persons who have shared illicit
drugs with a person who has serologically confirmed hepa-
titis A should receive hepatitis A vaccine, or IG and hepati-
tis A vaccine simultaneously. Consideration also should be
given to providing IG or hepatitis A vaccine to persons with
other types of ongoing, close personal contact (e.g., regular
babysitting) with a person with hepatitis A.
Child care centers. Hepatitis A vaccine or IG should be
administered to all previously unvaccinated staff members and
attendees of child care centers or homes if 1) one or more
cases of hepatitis A are recognized in children or employees or
2) cases are recognized in two or more households of center
attendees. In centers that do not provide care to children who
wear diapers, hepatitis A vaccine or IG need be administered
only to classroom contacts of the index patient. When an
outbreak occurs (i.e., hepatitis A cases in three or more fami-
lies), hepatitis A vaccine or IG also should be considered for
members of households that have children (center attendees)
in diapers.
Common-source exposure. If a food handler receives a diag-
nosis of hepatitis A, vaccine or IG should be administered to
other food handlers at the same establishment. Because
common-source transmission to patrons is unlikely, hepa-
titis A vaccine or IG administration to patrons typically is
not indicated but may be considered if 1) during the time
when the food handler was likely to be infectious, the food
handler both directly handled uncooked or cooked foods
and had diarrhea or poor hygienic practices and 2) patrons
can be identified and treated <2 weeks after the exposure.
In settings in which repeated exposures to HAV might have
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occurred (e.g., institutional cafeterias), stronger consider-
ation of hepatitis A vaccine or IG use could be warranted.
In the event of a common-source outbreak, postexposure
prophylaxis should not be provided to exposed persons
after cases have begun to occur because the 2-week period
after exposure during which IG or hepatitis A vaccine is
known to be effective will have been exceeded.
Schools, hospitals, and work settings. Hepatitis A
postexposure prophylaxis is not routinely indicated when
a single case occurs in an elementary or secondary school or
an office or other work setting, and the source of infection
is outside the school or work setting. Similarly, when a
person who has hepatitis A is admitted to a hospital, staff
members should not routinely be administered hepatitis A
postexposure prophylaxis; instead, careful hygienic prac-
tices should be emphasized. Hepatitis A vaccine or IG
should be administered to persons who have close contact
with index patients if an epidemiologic investigation indi-
cates HAV transmission has occurred among students in a
school or among patients or between patients and staff
members in a hospital.
II. Prevention of Hepatitis A Before
International Travel
Hepatitis A vaccination is recommended to prevent hepa-
titis A among travelers to countries with high or interme-
diate hepatitis A endemicity. Previously, however, because
few data were available regarding the immunogenicity of
hepatitis A vaccine during the 4 weeks immediately fol-
lowing administration of the first dose, ACIP recommended
that, for optimal protection, persons traveling to an area
where the risk for transmission was high <4 weeks after the
initial vaccine dose also could be administered IG (1). In
June 2007, ACIP concluded that if hepatitis A vaccine alone
can be recommended for prophylaxis after exposure to HAV,
vaccine also should be recommended for healthy interna-
tional travelers aged <40 years regardless of their scheduled
dates for departure. Similar to updated recommendations
for postexposure prophylaxis, ACIP recognized that, for
certain international travelers (e.g., older adults or those
with underlying medical conditions), the performance of
vaccine alone is unknown and clinical manifestations of
hepatitis A tend to be more severe. Hence, under the
updated recommendations for international travelers, for
optimal protection, IG can be considered in addition to
vaccine for older adults, immunocompromised persons, and
persons with chronic liver disease or other chronic medical
conditions who are traveling to an area within 2 weeks.
The following recommendation updates recommenda-
tions for prevention of hepatitis A among travelers departing
in <4 weeks to areas where prophylaxis is recommended
and consolidates other recommendations for prevention of
hepatitis A among international travelers (1). These rec-
ommendations replace previous ACIP recommendations for
preexposure protection against hepatitis A for travelers (1).
Recommendations for preexposure protection against
hepatitis A for travelers. All susceptible persons traveling
to or working in countries that have high or intermediate
hepatitis A endemicity are at increased risk for HAV infec-
tion and should be vaccinated or receive IG before depar-
ture.* Hepatitis A vaccination at the age-appropriate dose
is preferred to IG. Data are not available regarding the risk
for hepatitis A for persons traveling to certain areas of the
Caribbean, although prophylaxis should be considered if
travel to areas with questionable sanitation is anticipated.
Travelers to Australia, Canada, western Europe, Japan, or
New Zealand (i.e., countries in which endemicity is low)
are at no greater risk for infection than persons living or
traveling in the United States.
The first dose of hepatitis A vaccine should be administered
as soon as travel is considered. Based on limited data indicat-
ing equivalent postexposure efficacy of IG and vaccine among
healthy persons aged <40 years, 1 dose of single-antigen hepa-
titis A vaccine administered at any time before departure can
provide adequate protection for most healthy persons. How-
ever, no data are available for other populations or other hepa-
titis A vaccine formulations (e.g., Twinrix®). For optimal
protection, older adults, immunocompromised persons, and
persons with chronic liver disease or other chronic medical
conditions planning to depart to an area in <2 weeks should
receive the initial dose of vaccine and also simultaneously can
be administered IG (0.02 mL/kg) at a separate anatomic
injection site. Completion of the vaccine series according to
the licensed schedule is necessary for long-term protection.
Travelers who elect not to receive vaccine, are aged
<12 months, or are allergic to a vaccine component should
receive a single dose of IG (0.02 mL/kg), which provides
effective protection against hepatitis A for up to 3 months.
Such travelers whose travel period is expected to be
>2 months should be administered IG at 0.06 mL/kg;
administration must be repeated if the travel period is
>5 months. The full statement containing licensed vacci-
nation schedule and recommended dose of IG and vaccine
has been published previously (1).
Reported by: R Novak, PhD, I Williams, PhD, Div of Viral Hepatitis,
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention;
B Bell, MD, Office of the Director, National Center for Immunization and
Respiratory Diseases, CDC.
* Additional information is available at http://wwwn.cdc.gov/travel/yellowbook
ch4-hepa.aspx.
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West Nile Virus Update —
United States,
January 1–October 16, 2007
This report summarizes 2007 West Nile virus (WNV)
surveillance data reported to CDC through ArboNET as of
3 a.m. Mountain Daylight Time, October 16, 2007. A
total of 42 states have reported 3,022 cases of human WNV
illness to CDC (Table, Figure). A total of 1,646 (55%)
cases for which such data were available occurred in males;
median age of patients was 51 years (range: 15 months–97
years). Dates of illness onset ranged from January 8 to
October 9; a total of 76 cases were fatal.
A total of 265 presumptive West Nile viremic blood
donors (PVDs) have been reported to ArboNET during
2007. Of these, 46 were reported from California; 37 from
Texas; 24 from North Dakota; 21 from South Dakota; 20
from Colorado; 17 from Minnesota; 16 from Oklahoma;
13 from Montana; 12 from Mississippi; 11 from Missouri;
seven from Arizona; six from Ohio; five each from Iowa and
Utah; four each from Kentucky and New Mexico; three
each from Puerto Rico and Wyoming; two each from
Indiana and Pennsylvania; and one each from Louisiana,
New York, North Carolina, South Carolina, Tennessee, Vir-
ginia, and Wisconsin. Of the 265 PVDs, two persons (me-
dian age: 66 years [range: 60–71 years]) subsequently had
neuroinvasive illness, and 52 persons (median age: 48 years
[range: 18–79 years]) subsequently had West Nile fever.
TABLE. Number of human cases of West Nile virus (WNV)
illness, by state — United States, 2007*
West Other Total
Neuroinvasive Nile clinical/ reported
State disease† fever§ unspecified¶ to CDC** Deaths
Alabama 13 4 0 17 3
Arizona 28 14 20 62 0
Arkansas 10 5 0 15 1
California 143 191 9 343 14
Colorado 95 449 0 544 6
Connecticut 3 1 0 4 0
Delaware 1 0 0 1 0
Florida 3 0 0 3 1
Georgia 22 19 3 44 2
Idaho 6 96 2 104 1
Illinois 39 19 10 68 4
Indiana 6 4 0 10 1
Iowa 10 11 2 23 2
Kansas 11 26 0 37 1
Kentucky 3 0 0 3 0
Louisiana 1 1 0 2 0
Maryland 4 4 1 9 0
Massachusetts 3 3 0 6 0
Michigan 11 0 1 12 0
Minnesota 42 54 0 96 2
Mississippi 39 69 0 108 3
Missouri 52 9 0 61 2
Montana 36 157 0 193 3
Nebraska 18 117 0 135 3
Nevada 2 5 4 11 0
New Jersey 1 0 0 1 0
New Mexico 36 21 0 57 3
New York 10 1 0 11 1
North Dakota 49 303 0 352 2
Ohio 10 4 1 15 1
Oklahoma 48 37 1 86 7
Oregon 4 18 0 22 0
Pennsylvania 3 3 0 6 0
Rhode Island 0 1 0 1 0
South Carolina 2 2 0 4 0
South Dakota 48 158 0 206 5
Tennessee 4 2 1 7 1
Texas 89 20 0 109 5
Utah 21 26 0 47 1
Virginia 2 1 0 3 0
Wisconsin 3 3 0 6 0
Wyoming 15 149 14 178 1
Total 946 2,007 69 3,022 76
* As of October 16, 2007.
† Cases with neurologic manifestations (i.e., West Nile meningitis, West
Nile encephalitis, and West Nile myelitis).
§ Cases with no evidence of neuroinvasion.
¶ Illnesses for which sufficient clinical information was not provided.
** Total number of human cases of WNV illness reported to ArboNET by
state and local health departments.
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Prevention Teaching and Research, the Association of
Schools of Public Health (ASPH), and the Council of Col-
leges of Arts and Sciences (CCAS). The conference was sup-
ported by the Josiah Macy, Jr. Foundation through a grant
to the Healthy People Curriculum Task Force (HPCTF), a
coalition of seven health-profession educational associations,
including allopathic and osteopathic medicine, dentistry,
nursing and nurse practitioners, pharmacy, and physician
assistants. Participating in the conference were representa-
tives from CDC, the Association of American Colleges and
Universities, and HPCTF.
Conference attendees agreed that undergraduate public
health education can help produce an educated citizenry that
is better prepared to cope with public health challenges rang-
ing from acquired immunodeficiency syndrome to aging, avian
influenza, and health-care costs. Conference working groups
recommended that two introductory courses, Public Health
101 and Epidemiology 101, be offered by all U.S. colleges
and universities to fulfill undergraduate social science and
science distribution requirements, respectively. The groups
further recommended that high-quality minors in public
health should be developed, with core courses, experience-
based learning, and focus areas such as global health. The
full recommendations from the conference have been
published online by CCAS at http://www.ccas.net.
The modern era of undergraduate public health educa-
tion began at Johns Hopkins University in the mid-1970s,
when a public health major was approved through the
School of Arts and Sciences in collaboration with what was
then the School of Hygiene and Public Health. After slow
growth in the 1980s, interest in undergraduate public
health education grew rapidly in the 1990s. By the end of
the 20th century, a substantial number of schools of pub-
lic health were experimenting with undergraduate courses,
minors, and majors. Programs in public health also were
revising professionally focused curricula and developing
broader approaches to undergraduate public health educa-
tion (2,3).
Recent surveys indicate that the majority of the approxi-
mately 40 accredited public health schools (ASPH, unpub-
lished data, 2006) and approximately 60 accredited public
health programs (Association for Prevention Teaching and
Research, unpublished data, 2006) offer undergraduate courses
in public health. However, public health courses are offered
rarely among the 1,900 colleges and universities that have no
public health schools or programs yet might choose to
include public health in their arts and sciences curricula.
The conference working groups recommended that Pub-
lic Health 101 and Epidemiology 101 be designed to fit
within the broadest possible array of arts and science
In addition, 1,489 dead corvids and 435 other dead birds
with WNV infection have been reported in 34 states and
New York City during 2007. WNV infections have been
reported in horses in 31 states, in three canines in Idaho
and Oregon, in 26 squirrels in California and Oregon, and
in three unidentified animal species in Idaho and Montana.
WNV seroconversions have been reported in 637 sentinel
chicken flocks in 11 states (Arizona, Arkansas, California,
Delaware, Florida, Iowa, North Carolina, North Dakota,
Oregon, Utah, and Virginia) and Puerto Rico. A total of
7,208 WNV-positive mosquito pools have been reported
from 36 states, the District of Columbia, and New York
City.
Additional information about national WNV activity is
available from CDC at http://www.cdc.gov/ncidod/dvbid/
westnile/index.htm and at http://westnilemaps.usgs.gov.
Notice to Readers
Recommendations for Public Health
Curriculum — Consensus Conference
on Undergraduate Public Health
Education, November 2006
The Institute of Medicine of the National Academies has
recommended that all undergraduates have access to educa-
tion in public health (1). To implement this recommenda-
tion, a Consensus Conference on Undergraduate Public
Health Education was convened November 7–8, 2006, in
Boston, Massachusetts. The conference included leaders in
public health, arts and sciences, and health-professions
education and was sponsored by the Association for
FIGURE. Areas reporting West Nile virus (WNV) activity —
United States, 2007*
* As of October 16, 2007.
Human WNV illness
Nonhuman WNV infection only
PR
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QuickStats
from the national center for health statistics
Age-Adjusted Death Rates,* by Race and Sex — United States, 2005
* Per 100,000 U.S. standard population.
In 2005, black males had the highest age-adjusted death rate compared with females, white males, and all
races. The higher rate for black males reflects higher death rates for most of the leading causes of death.
SOURCE: Kung HC, Hoyert DL, Xu JQ, Murphy SL. Deaths: preliminary data for 2005. Hyattsville, MD: US


















education programs and institutional types. The Public
Health 101 working group said making that course a part
of general education can stimulate critical thinking and
decision making, provide students with a methodology for
understanding populations, and expose students to ongo-
ing health-care and policy matters. Similarly, the Epide-
miology 101 working group noted that epidemiology can
play a key role in general education if taught broadly as a
method for critical thinking. Epidemiology 101, the group
said, can enable students to acquire quantitative and infor-
mation literacy; learn the methods, ethics, and applications
of the scientific method; and recognize the link between
natural and social sciences, thus enriching their understand-
ing of public policy and other population-based disciplines.
Methods for integrating recommendations from the con-
ference into the nation’s long-term strategy for public health
also were discussed. These included 1) websites to provide
information on undergraduate public health and share
curriculum materials, 2) faculty development measures to
assist colleges and universities in developing new introduc-
tory public health courses, 3) encouragement of applicants
by health professions education and graduate public health
degree programs to enroll in introductory undergraduate
public health courses, 4) continued discussion of approaches
for developing minors in public health and global health
in institutions with and without schools or programs in
public health, and 5) participation by public-health prac-
titioners in experiential or service-learning and other
components of undergraduate education.
References
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QuickGuide
Recommended Adult Immunization
Schedule — United States,
October 2007–September 2008
The Advisory Committee on Immunization Practices (ACIP)
annually reviews the recommended Adult Immunization Schedule
to ensure that the schedule reflects current recommendations for
the licensed vaccines. In June 2007, ACIP approved the Adult
Immunization Schedule for October 2007–September 2008.
Additional information is available as follows: schedule (in English
and Spanish) at http://www.cdc.gov/vaccines/recs/schedules/adult-
schedule.htm; adult vaccinations at http://www.cdc.gov/vaccines/
default.htm; ACIP statements for specific vaccines at http://www.
cdc.gov/vaccines/pubs/acip-list.htm; and reporting adverse events
at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
Changes for October 2007–September 2008
Age-Based Schedule (Figure 1)
• The yellow bar for varicella vaccine has been extended through
all age groups, indicating that the vaccine is recommended for all
adults without evidence of immunity to varicella.
• Zoster vaccine has been added, with a yellow bar indicating that
the vaccine is recommended for persons aged >60 years.
Medical/Other Indications Schedule (Figure 2)
• The title has been changed to “Vaccines that might be indicated
for adults based on medical and other indications,” indicating
that not all of the vaccines are recommended based on medical
indications.
• The word “contraindicated” has been added to the red bars and
removed from the legend.
• The “immunocompromising conditions” column heading has
been shortened by removing the list of conditions.
• The “human immunodeficiency virus (HIV) infection” column
has been moved next to the “immunocompromising conditions”
column.
• The HIV column has been split into CD4+ T lymphocyte counts
of <200 cells/µL and >200 cells/µL.
• The indication “recipients of clotting factor concentrates” has
been removed from the column heading “chronic liver disease”
because only one vaccine has this recommendation. The indica-
tion remains in the hepatitis A vaccine footnote.
• The varicella vaccine yellow bar has been extended to include
persons infected with HIV who have CD4+ T lymphocyte counts
of >200 cells/µL (1).
• The influenza vaccine yellow bar for “health-care personnel”
indicates that health-care personnel can receive either trivalent
inactivated influenza vaccine (TIV) or live, attenuated influenza
vaccine (LAIV).
• The yellow bar for influenza vaccine has been extended to
include persons in the “asplenia” risk group.
• The bar for meningococcal vaccine has been revised to indicate
that 1 or more doses might be indicated.
• Zoster vaccine has been added to the schedule with a yellow bar
to indicate that the vaccine is recommended for all indications
except pregnancy, immunocompromising conditions, and HIV.
A red bar, indicating a contraindication, has been inserted for
pregnancy, immunocompromising conditions, and HIV infec-
tion with a CD4+ T lymphocyte count of <200 cells/µL.
Footnotes (Figures 1 and 2)
• Text for vaccine contraindications in pregnancy has been removed
from the footnotes of human papillomavirus (HPV) (#2); measles,
mumps, rubella (MMR) (#3); and varicella (#4) to be consistent with
the intent of the footnotes to summarize the indications for vaccine
use. Pregnancy contraindications are indicated with a red bar.
• The HPV footnote (#2) has been revised to clarify evidence of
prior infection, clarify that HPV vaccine is not specifically indi-
cated based on medical conditions, and indicate that efficacy and
immunogenicity might be lower in persons with certain medical
conditions.
• The varicella footnote (#4) has been revised to clarify that birth
before 1980 for immunocompromised persons is not evidence of
immunity and to add a requirement for evidence of immunity.
• The pneumococcal polysaccharide vaccine (PPV) footnote (#6)
has been revised by adding chronic alcoholism and cerebrospinal
fluid leaks and deleting the immunocompromising conditions.
• The hepatitis B footnote (#9) has been revised by removing per-
sons who receive clotting factor concentrates as a risk group and
by clarifying the special formulations dose.
• The meningococcal vaccine footnote (#10) has been revised to
clarify that persons who remain at increased risk for infection
might be indicated for revaccination.
• A footnote (#11) has been added to reflect ACIP recommenda-
tions for herpes zoster vaccination for persons aged >60 years.
• A footnote (#13) has been added to provide a reference for vac-
cines in persons with immunocompromising conditions.
Reference
1. CDC. Prevention of varicella: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR 2007;
56(No. RR-4).
The Recommended Adult Immunization Schedule has been approved by the Advisory
Committee on Immunization Practices, the American Academy of Family Physicians, the
American College of Obstetricians and Gynecologists, and the American College of Physicians.
The standard MMWR footnote format has been modified for publication of this schedule.
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1. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
Tdap should replace a single dose of Td for adults aged <65 years
who have not previously received a dose of Tdap. Only one of two
Tdap products (Adacel® [Sanofi Pasteur]) is licensed for use in adults.
Adults with uncertain histories of a complete primary vaccination
series with tetanus and diphtheria toxoid–containing vaccines should
begin or complete a primary vaccination series. A primary series for
adults is 3 doses of tetanus and diphtheria toxoid–containing vaccines;
administer the first 2 doses at least 4 weeks apart and the third dose
6–12 months after the second. However, Tdap can substitute for any
one of the doses of Td in the 3-dose primary series. The booster dose
of tetanus and diphtheria toxoid–containing vaccine should be
administered to adults who have completed a primary series and if the
last vaccination was received >10 years previously. Tdap or Td vaccine
may be used, as indicated.
If the person is pregnant and received the last Td vaccination >10
years previously, administer Td during the second or third trimester; if
the person received the last Td vaccination in <10 years, administer
Tdap during the immediate postpartum period. A one-time adminis-
tration of 1 dose of Tdap with an interval as short as 2 years from a
previous Td vaccination is recommended for postpartum women, close
contacts of infants aged <12 months, and all health-care workers with
direct patient contact. In certain situations, Td can be deferred during
pregnancy and Tdap substituted in the immediate postpartum period,
or Tdap can be administered instead of Td to a pregnant woman after
an informed discussion with the woman.
Consult the ACIP statement for recommendations for administering
Td as prophylaxis in wound management.
2. Human papillomavirus (HPV) vaccination
HPV vaccination is recommended for all females aged <26 years
who have not completed the vaccine series. History of genital warts,
abnormal Papanicolaou test, or positive HPV DNA test is not evidence
of prior infection with all vaccine HPV types; HPV vaccination is still
recommended for these persons.
Ideally, vaccine should be administered before potential exposure
to HPV through sexual activity; however, females who are sexually
active should still be vaccinated. Sexually active females who have
not been infected with any of the HPV vaccine types receive the full
benefit of the vaccination. Vaccination is less beneficial for females
who have already been infected with one or more of the HPV vaccine
types.
A complete series consists of 3 doses. The second dose should be
administered 2 months after the first dose; the third dose should be
administered 6 months after the first dose.
Although HPV vaccination is not specifically recommended for
females with the medical indications described in Figure 2, “Vaccines
that might be indicated for adults based on medical and other
indications,” it is not a live-virus vaccine and can be administered.
However, immune response and vaccine efficacy might be less than
in persons who do not have the medical indications described or who
are immunocompetent.
3. Measles, mumps, rubella (MMR) vaccination
Measles component: adults born before 1957 can be considered
immune to measles. Adults born during or after 1957 should receive
>1 dose of MMR unless they have a medical contraindication,
documentation of >1 dose, history of measles based on health-care
provider diagnosis, or laboratory evidence of immunity.
A second dose of MMR is recommended for adults who 1) have
been recently exposed to measles or are in an outbreak setting; 2)
have been previously vaccinated with killed measles vaccine; 3) have
been vaccinated with an unknown type of measles vaccine during
1963–1967; 4) are students in postsecondary educational institutions;
5) work in a health-care facility; or 6) plan to travel internationally.
Mumps component: adults born before 1957 can generally be














1-dose Td booster every 10 yrs
1–2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
1 or 2 doses 1 dose
Influenza *5
1 or more doses
1 dose
1 dose annually1 dose annually
3 doses (0, 1–2, 4–6 mos)
Human papillomavirus
(HPV) *2
Substitute 1 dose of Tdap for Td
3 doses
(females)
(0, 2, 6 mos)
For all persons in this category who meet the age requirements
and who lack evidence of immunity (e.g., lack documentation
of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is





2 doses (0, 4–8 wks)
* Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read along with the footnotes, which are on pages Q2–Q4 of this schedule.
Approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians,
the American College of Obstetricians and Gynecologists, and the American College of Physicians.
Complete statements from ACIP are available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
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considered immune to mumps. Adults born during or after 1957 should
receive 1 dose of MMR unless they have a medical contraindication,
history of mumps based on health-care provider diagnosis, or laboratory
evidence of immunity.
A second dose of MMR is recommended for adults who 1) are in an
age group that is affected during a mumps outbreak; 2) are students
in postsecondary educational institutions; 3) work in a health-care
facility; or 4) plan to travel internationally. For unvaccinated health-
care workers born before 1957 who do not have other evidence of
mumps immunity, consider administering 1 dose on a routine basis
and strongly consider administering a second dose during an outbreak.
Rubella component: administer 1 dose of MMR vaccine to women
whose rubella vaccination history is unreliable or who lack laboratory
evidence of immunity. For women of childbearing age, regardless of
birth year, routinely determine rubella immunity and counsel women
regarding congenital rubella syndrome. Women who do not have
evidence of immunity should receive MMR vaccine on completion or
termination of pregnancy and before discharge from the health-care
facility.
4. Varicella vaccination
All adults without evidence of immunity to varicella should receive
2 doses of single-antigen varicella vaccine unless they have a medical
contraindication. Special consideration should be given to those who 1)
have close contact with persons at high risk for severe disease (e.g.,
health-care personnel and family contacts of immunocompromised
persons) or 2) are at high risk for exposure or transmission (e.g., teachers;
child care employees; residents and staff members of institutional
settings, including correctional institutions; college students; military
personnel; adolescents and adults living in households with children;
nonpregnant women of childbearing age; and international travelers).
Evidence of immunity to varicella in adults includes any of the
following: 1) documentation of 2 doses of varicella vaccine at least
4 weeks apart; 2) U.S.-born before 1980 (although for health-care
personnel and pregnant women, birth before 1980 should not be
considered evidence of immunity); 3) history of varicella based on
diagnosis or verification of varicella by a health-care provider (for a
patient reporting a history of or presenting with an atypical case, a
mild case, or both, health-care providers should seek either an
epidemiologic link with a typical varicella case or to a laboratory-
confirmed case or evidence of laboratory confirmation, if it was
performed at the time of acute disease); 4) history of herpes zoster
based on health-care provider diagnosis; or 5) laboratory evidence of
immunity or laboratory confirmation of disease.
Assess pregnant women for evidence of varicella immunity. Women
who do not have evidence of immunity should receive the first dose of
varicella vaccine upon completion or termination of pregnancy and
before discharge from the health-care facility. The second dose should
be administered 4–8 weeks after the first dose.
5. Influenza vaccination
Medical indications: chronic disorders of the cardiovascular or
pulmonary systems, including asthma; chronic metabolic diseases,
including diabetes mellitus, renal or hepatic dysfunction, hemoglobino-
pathies, or immunosuppression (including immunosuppression caused
by medications or human immunodeficiency virus [HIV]); any
condition that compromises respiratory function or the handling of
respiratory secretions or that can increase the risk of aspiration (e.g.,
cognitive dysfunction, spinal cord injury, or seizure disorder or other
neuromuscular disorder); and pregnancy during the influenza season.
No data exist on the risk for severe or complicated influenza disease
among persons with asplenia; however, influenza is a risk factor for
secondary bacterial infections that can cause severe disease among
persons with asplenia.

























































1 dose Td booster every 10 yrs
1 or 2 doses
1 dose TIV annually
Substitute 1 dose of Tdap for Td







2 doses (0, 4–8 wks)
Contraindicated
Contraindicated
1 dose TIV or
LAIV annually
3 doses (0, 1–2, 4–6 mos)
1 or more doses




For all persons in this category who meet the age requirements
and who lack evidence of immunity (e.g., lack documentation
of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is
(e.g., on the basis of medical, occupational, lifestyle,
or other indications)
present* Covered by the Vaccine Injury Compensation Program.
HIV infection
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Occupational indications: health-care personnel and employees of
long-term–care and assisted-living facilities.
Other indications: residents of nursing homes and other long-term–
care and assisted-living facilities; persons likely to transmit influenza
to persons at high risk (e.g., in-home household contacts and caregivers
of children aged 0–59 months, or persons of all ages with high-risk
conditions); and anyone who would like to be vaccinated. Healthy,
nonpregnant adults aged <49 years without high-risk medical conditions
who are not contacts of severely immunocompromised persons in
special care units can receive either intranasally administered live,
attenuated influenza vaccine (FluMist®) or inactivated vaccine. Other
persons should receive the inactivated vaccine.
6. Pneumococcal polysaccharide vaccination
Medical indications: chronic pulmonary disease (excluding asthma);
chronic cardiovascular diseases; diabetes mellitus; chronic liver
diseases, including liver disease as a result of alcohol abuse (e.g.,
cirrhosis); chronic alcoholism, chronic renal failure, or nephrotic
syndrome; functional or anatomic asplenia (e.g., sickle cell disease or
splenectomy [if elective splenectomy is planned, vaccinate at least 2
weeks before surgery]); immunosuppressive conditions; and cochlear
implants and cerebrospinal fluid leaks. Vaccinate as close to HIV
diagnosis as possible.
Other indications: Alaska Natives and certain American Indian
populations and residents of nursing homes or other long-term–care
facilities.
7. Revaccination with pneumococcal polysaccharide vaccine
One-time revaccination after 5 years for persons with chronic renal
failure or nephrotic syndrome; functional or anatomic asplenia (e.g.,
sickle cell disease or splenectomy); or immunosuppressive conditions.
For persons aged >65 years, one-time revaccination if they were
vaccinated >5 years previously and were aged <65 years at the time
of primary vaccination.
8. Hepatitis A vaccination
Medical indications: persons with chronic liver disease and persons
who receive clotting factor concentrates.
Behavioral indications: men who have sex with men and persons
who use illegal drugs.
Occupational indications: persons working with hepatitis A virus
(HAV)-infected primates or with HAV in a research laboratory setting.
Other indications: persons traveling to or working in countries that
have high or intermediate endemicity of hepatitis A (a list of countries
is available at http://wwwn.cdc.gov/travel/contentdiseases.aspx) and
any person seeking protection from HAV infection.
Single-antigen vaccine formulations should be administered in a
2-dose schedule at either 0 and 6–12 months (Havrix®), or 0 and
6–18 months (Vaqta®). If the combined hepatitis A and hepatitis B
vaccine (Twinrix®) is used, administer 3 doses at 0, 1, and 6 months.
9. Hepatitis B vaccination
Medical indications: persons with end-stage renal disease, including
patients receiving hemodialysis; persons seeking evaluation or
treatment for a sexually transmitted disease (STD); persons with HIV
infection; and persons with chronic liver disease.
Occupational indications: health-care personnel and public-safety workers
who are exposed to blood or other potentially infectious body fluids.
Behavioral indications: sexually active persons who are not in a
long-term, mutually monogamous relationship (e.g., persons with more
than one sex partner during the previous 6 months); current or recent
injection-drug users; and men who have sex with men.
Other indications: household contacts and sex partners of persons
with chronic hepatitis B virus (HBV) infection; clients and staff members
of institutions for persons with developmental disabilities; international
travelers to countries with high or intermediate prevalence of chronic
HBV infection (a list of countries is available at http://wwwn.cdc.gov/
travel/contentdiseases.aspx); and any adult seeking protection from
HBV infection.
Settings where hepatitis B vaccination is recommended for all adults:
STD treatment facilities; HIV testing and treatment facilities; facilities
providing drug-abuse treatment and prevention services; health-care
settings targeting services to injection-drug users or men who have
sex with men; correctional facilities; end-stage renal disease programs
and facilities for chronic hemodialysis patients; and institutions and
nonresidential day care facilities for persons with developmental
disabilities.
Special formulation indications: for adult patients receiving
hemodialysis and other immunocompromised adults, 1 dose of 40 µg/mL
(Recombivax HB®) or 2 doses of 20 µg/mL (Engerix-B®), administered
simultaneously.
10. Meningococcal vaccination
Medical indications: adults with anatomic or functional asplenia or
terminal complement component deficiencies.
Other indications: first-year college students living in dormitories;
microbiologists who are routinely exposed to isolates of Neisseria
meningitidis; military recruits; and persons who travel to or live in
countries in which meningococcal disease is hyperendemic or epidemic
(e.g., the “meningitis belt” of sub-Saharan Africa during the dry season
[December–June]), particularly if their contact with local populations
will be prolonged. Vaccination is required by the government of Saudi
Arabia for all travelers to Mecca during the annual Hajj.
Meningococcal conjugate vaccine is preferred for adults with any of
the preceding indications who are aged <55 years, although
meningococcal polysaccharide vaccine (MPSV4) is an acceptable
alternative. Revaccination after 3–5 years might be indicated for adults
previously vaccinated with MPSV4 who remain at increased risk for
infection (e.g., persons residing in areas in which disease is epidemic).
11. Herpes zoster vaccination
A single dose of zoster vaccine is recommended for adults aged
>60 years regardless of whether they report a prior episode of herpes
zoster. Persons with chronic medical conditions may be vaccinated
unless a contraindication or precaution exists for their condition.
12. Selected conditions for which Haemophilus influenzae type b
(Hib) vaccine may be used
Hib conjugate vaccines are licensed for children aged 6 weeks–
71 months. No efficacy data are available on which to base a
recommendation concerning use of Hib vaccine for older children and
adults with the chronic conditions associated with an increased risk
for Hib disease. However, studies suggest good immunogenicity in
patients who have sickle cell disease, leukemia, or HIV infection or
who have had splenectomies; administering vaccine to these patients
is not contraindicated.
13. Immunocompromising conditions
Inactivated vaccines generally are acceptable (e.g., pneumococcal,
meningococcal, and influenza [trivalent inactivated influenza vaccine])
and live vaccines generally are avoided in persons with immune
deficiencies or immune suppressive conditions. Information on specific
conditions is available at http://www.cdc.gov/vaccines/pubs/acip-
list.htm.
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons aged >19 years, as of October 1, 2007.
Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed
recommendations on all vaccines, including those used primarily for travelers or those issued during the year, consult the manufacturers’ package inserts and the complete statements from the
Advisory Committee on Immunization Practices (available at http://www.cdc.gov/vaccines/pubs/acip-list.htm).
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available
at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at http://www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for
vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States,
week ending October 13, 2007 (41st Week)*
5-year
Current Cum weekly Total cases reported for previous years
Disease week 2007 average† 2006 2005 2004 2003 2002 States reporting cases during current week (No.)
—: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.
* Incidence data for reporting year 2007 are provisional, whereas data for 2002, 2003, 2004, 2005, and 2006 are finalized.
† Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5
preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
§ Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-
Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
** Data for H. influenzae (all ages, all serotypes) are available in Table II.
†† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting
influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data
management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 71 cases were reported for the 2006–07 flu season.
¶¶ No measles cases were reported for the current week.
*** Data for meningococcal disease (all serogroups) are available in Table II.
††† No rubella cases were reported for the current week.
§§§ Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
Anthrax — — — 1 — — — 2
Botulism:
foodborne — 15 0 20 19 16 20 28
infant — 63 2 97 85 87 76 69
other (wound & unspecified) — 18 1 48 31 30 33 21
Brucellosis 1 94 2 121 120 114 104 125 CA (1)
Chancroid 2 24 1 33 17 30 54 67 WI (1), TX (1)
Cholera — 3 0 9 8 5 2 2
Cyclosporiasis§ 1 84 1 136 543 171 75 156 FL (1)
Diphtheria — — 0 — — — 1 1
Domestic arboviral diseases§,¶:
California serogroup — 24 4 67 80 112 108 164
eastern equine — 3 0 8 21 6 14 10
Powassan — 1 — 1 1 1 — 1
St. Louis — 2 1 10 13 12 41 28
western equine — — — — — — — —
Ehrlichiosis§:
human granulocytic 4 384 10 646 786 537 362 511 NY (3), FL (1)
human monocytic 8 490 9 578 506 338 321 216 NY (2), NC (1), FL (2), AR (3)
human (other & unspecified) 1 128 1 231 112 59 44 23 MD (1)
Haemophilus influenzae,**
  invasive disease (age <5 yrs):
serotype b — 12 0 29 9 19 32 34
nonserotype b 2 106 2 175 135 135 117 144 OH (1), AZ (1)
unknown serotype 1 164 3 179 217 177 227 153 AZ (1)
Hansen disease§ — 41 1 66 87 105 95 96
Hantavirus pulmonary syndrome§ — 19 0 40 26 24 26 19
Hemolytic uremic syndrome, postdiarrheal§ 5 169 5 288 221 200 178 216 MN (1), MO (1), GA (1), TN (1), CA (1)
Hepatitis C viral, acute 7 517 20 802 652 713 1,102 1,835 TN (2), OK (4), TX (1)
HIV infection, pediatric (age <13 yrs)†† — — 5 52 380 436 504 420
Influenza-associated pediatric mortality§,§§ — 73 — 43 45 — N N
Listeriosis 13 503 21 875 896 753 696 665 VT (1), NY (1), OH (2), MN (1), NC (3), FL (2),
UT (1), CA (1), AK (1)
Measles¶¶ — 30 0 55 66 37 56 44
Meningococcal disease, invasive***:
A, C, Y, & W-135 2 210 4 318 297 — — — IN (1), TX (1)
serogroup B — 102 2 193 156 — — —
other serogroup 1 21 0 32 27 — — — NC (1)
unknown serogroup 4 473 10 651 765 — — — ME (1), NYC (1), MI (1), MN (1)
Mumps 3 603 13 6,584 314 258 231 270 ME (1), FL (2)
Novel influenza A virus infections — 3 — N N N N N
Plague — 4 0 17 8 3 1 2
Poliomyelitis, paralytic — — 0 — 1 — — —
Poliovirus infection, nonparalytic§ — — — N N N N N
Psittacosis§ — 6 0 21 16 12 12 18
Q fever§ — 133 2 169 136 70 71 61
Rabies, human — — 0 3 2 7 2 3
Rubella††† — 11 0 11 11 10 7 18
Rubella, congenital syndrome — — — 1 1 — 1 1
SARS-CoV§,§§§ — — — — — — 8 N
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 77 1 125 129 132 161 118
Syphilis, congenital (age <1 yr) 3 324 8 380 329 353 413 412 FL (1), LA (1), TX (1)
Tetanus 1 14 1 41 27 34 20 25 FL (1)
Toxic-shock syndrome (staphylococcal)§ 1 64 1 101 90 95 133 109 NC (1)
Trichinellosis — 5 0 15 16 5 6 14
Tularemia — 100 3 95 154 134 129 90
Typhoid fever 4 266 8 353 324 322 356 321 OH (1), FL (2), CA (1)
Vancomycin-intermediate Staphylococcus aureus§ — 18 0 6 2 — N N
Vancomycin-resistant Staphylococcus aureus§ — — 0 1 3 1 N N
Vibriosis (noncholera Vibrio species infections)§ 5 255 2 N N N N N GA (1), FL (1), CA (3)
Yellow fever — — — — — — — 1
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
†
Chlamydia refers to genital infections caused by Chlamydia trachomatis.
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
Chlamydia† Coccidioidomycosis Cryptosporidiosis
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 11,326 20,421 25,327 800,902 804,763 64 142 658 5,840 6,347 224 82 942 8,096 4,506
New England 824 713 1,357 27,246 26,059 — 0 1 2 — 4 4 37 244 334
Connecticut 368 223 829 8,134 7,436 N 0 0 N N — 0 37 37 38
Maine§ 42 50 74 2,021 1,780 — 0 0 — — — 1 6 41 36
Massachusetts 339 305 600 12,347 11,829 — 0 0 — — — 2 7 80 163
New Hampshire — 39 70 1,612 1,543 — 0 1 2 — — 1 5 44 40
Rhode Island§ 53 63 106 2,449 2,532 — 0 0 — — 2 0 3 8 14
Vermont§ 22 19 45 683 939 N 0 0 N N 2 1 3 34 43
Mid. Atlantic 2,040 2,727 4,284 110,702 98,146 — 0 0 — — 8 10 109 989 536
New Jersey 215 401 528 16,034 15,934 N 0 0 N N — 0 2 9 41
New York (Upstate) 510 515 2,758 21,002 18,935 N 0 0 N N 8 3 20 199 130
New York City 1,149 925 1,682 38,815 32,063 N 0 0 N N — 1 6 51 122
Pennsylvania 166 764 1,760 34,851 31,214 N 0 0 N N — 4 103 730 243
E.N. Central 1,262 3,123 6,213 129,855 135,663 — 1 3 24 36 58 18 117 1,364 1,145
Illinois 472 944 1,367 37,489 42,481 — 0 0 — — — 2 10 110 178
Indiana 227 398 646 16,268 15,601 — 0 0 — — 6 1 12 82 71
Michigan 360 713 1,059 27,790 28,146 — 0 3 16 32 2 2 10 138 121
Ohio 93 704 3,640 33,621 33,078 — 0 2 8 4 28 5 61 476 294
Wisconsin 110 371 443 14,687 16,357 N 0 0 N N 22 6 51 558 481
W.N. Central 625 1,178 1,429 46,534 48,789 — 0 54 6 1 41 13 121 1,191 716
Iowa 186 161 252 6,858 6,594 N 0 0 N N 3 2 59 514 157
Kansas — 151 294 6,194 6,278 N 0 0 N N — 1 15 76 70
Minnesota — 231 314 8,106 10,184 — 0 54 — — 34 3 34 208 155
Missouri 339 453 565 18,249 18,066 — 0 1 6 1 — 2 13 115 165
Nebraska§ 27 103 183 3,956 4,152 N 0 0 N N 3 1 21 124 84
North Dakota 18 27 61 1,143 1,442 N 0 0 N N 1 0 11 15 9
South Dakota 55 49 84 2,028 2,073 N 0 0 N N — 2 16 139 76
S. Atlantic 2,478 3,999 6,760 157,720 154,289 — 0 1 3 3 33 20 66 903 893
Delaware 30 66 140 2,650 2,796 — 0 0 — — — 0 4 16 13
District of Columbia — 103 166 4,303 2,303 — 0 0 — — — 0 2 3 12
Florida 1,139 1,115 1,767 45,719 38,877 N 0 0 N N 22 11 35 499 381
Georgia 1 628 3,822 19,385 27,851 N 0 0 N N 5 4 22 171 224
Maryland§ 278 399 696 15,804 16,785 — 0 1 3 3 — 0 2 24 15
North Carolina — 562 1,905 22,648 26,405 — 0 0 — — 6 1 9 78 81
South Carolina§ 639 497 3,030 25,524 18,115 N 0 0 N N — 1 5 57 117
Virginia§ 379 485 685 19,381 18,860 N 0 0 N N — 1 4 45 42
West Virginia 12 57 91 2,306 2,297 N 0 0 N N — 0 5 10 8
E.S. Central 847 1,451 2,044 55,886 59,943 — 0 0 — — 10 3 60 474 144
Alabama§ — 348 558 12,235 18,560 N 0 0 N N — 1 12 71 52
Kentucky 78 148 691 6,313 6,437 N 0 0 N N 6 1 39 219 34
Mississippi 351 355 959 15,497 14,898 N 0 0 N N — 0 10 74 22
Tennessee§ 418 505 724 21,841 20,048 N 0 0 N N 4 1 19 110 36
W.S. Central 1,820 2,288 2,971 95,252 91,390 — 0 1 1 1 9 5 41 259 327
Arkansas§ 320 168 288 7,202 6,496 N 0 0 N N — 0 8 25 18
Louisiana 157 359 855 15,009 14,374 — 0 1 1 1 — 1 5 39 73
Oklahoma 267 266 467 10,464 9,554 N 0 0 N N 9 1 11 98 32
Texas§ 1,076 1,490 1,952 62,577 60,966 N 0 0 N N — 2 29 97 204
Mountain 108 1,290 1,811 46,784 53,717 51 91 293 3,763 4,365 59 6 570 2,555 340
Arizona 41 474 897 16,142 17,207 44 89 293 3,639 4,248 — 0 6 38 23
Colorado — 240 369 7,581 12,871 N 0 0 N N — 1 25 136 61
Idaho§ 67 56 253 2,883 2,234 N 0 0 N N 20 0 71 335 30
Montana§ — 47 82 1,488 2,002 N 0 0 N N 2 1 18 56 125
Nevada§ — 178 293 7,279 6,652 2 1 5 50 51 1 0 3 17 9
New Mexico§ — 153 394 6,354 7,713 — 0 2 17 18 — 1 7 83 37
Utah — 104 209 4,140 3,870 5 1 7 54 46 35 0 497 1,846 15
Wyoming§ — 23 38 917 1,168 — 0 1 3 2 1 0 8 44 40
Pacific 1,322 3,364 4,362 130,923 136,767 13 44 311 2,041 1,941 2 1 19 117 71
Alaska 82 88 157 3,445 3,457 N 0 0 N N — 0 2 3 4
California 957 2,666 3,627 105,454 107,284 13 44 311 2,041 1,941 — 0 0 — —
Hawaii 3 103 133 4,128 4,533 N 0 0 N N — 0 4 6 4
Oregon§ 260 159 394 6,835 7,494 N 0 0 N N 2 1 15 108 63
Washington 20 314 621 11,061 13,999 N 0 0 N N — 0 0 — —
American Samoa U 0 32 U U U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam 1 4 207 389 708 — 0 0 — — — 0 0 — —
Puerto Rico 90 120 544 6,009 3,928 N 0 0 N N N 0 0 N N
U.S. Virgin Islands U 3 7 U U U 0 0 U U U 0 0 U U
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
Haemophilus influenzae, invasive
Giardiasis Gonorrhea All ages, all serotypes†
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 301 304 1,513 12,637 14,002 3,589 6,649 8,941 260,282 280,879 12 45 184 1,755 1,793
New England 9 26 52 1,111 1,161 125 109 259 4,338 4,375 — 3 19 142 141
Connecticut — 6 18 284 240 62 45 204 1,642 1,751 — 0 7 40 41
Maine§ 2 4 10 157 138 — 2 8 98 99 — 0 2 9 16
Massachusetts — 10 26 463 511 53 51 96 2,105 1,915 — 2 6 69 62
New Hampshire — 0 3 20 21 — 3 8 119 156 — 0 2 15 10
Rhode Island§ 5 0 16 57 96 10 8 18 329 397 — 0 10 7 4
Vermont§ 2 3 10 130 155 — 1 5 45 57 — 0 1 2 8
Mid. Atlantic 46 56 127 2,138 2,766 464 714 1,537 28,885 26,109 2 10 27 358 360
New Jersey — 5 11 142 390 112 115 159 4,669 4,249 — 1 5 50 63
New York (Upstate) 42 24 108 898 942 137 116 1,035 5,401 4,939 2 3 15 104 113
New York City 4 15 24 608 775 155 204 346 8,180 8,051 — 2 6 78 67
Pennsylvania — 13 29 490 659 60 240 586 10,635 8,870 — 3 10 126 117
E.N. Central 40 46 77 1,819 2,249 507 1,230 2,577 52,257 56,069 1 6 15 206 302
Illinois — 12 23 474 565 174 351 498 13,931 15,953 — 1 6 48 92
Indiana N 0 0 N N 96 166 307 7,012 6,944 — 1 7 45 65
Michigan 2 12 20 441 568 159 286 747 11,314 11,780 — 0 5 21 23
Ohio 28 15 37 642 641 30 314 1,556 14,869 15,894 1 2 5 83 65
Wisconsin 10 7 19 262 475 48 129 181 5,131 5,498 — 0 2 9 57
W.N. Central 14 20 553 879 1,525 142 373 512 14,753 15,303 — 3 24 106 120
Iowa 1 5 21 230 241 23 39 60 1,496 1,474 — 0 1 1 1
Kansas — 3 8 108 164 — 42 86 1,770 1,768 — 0 2 9 16
Minnesota — 0 514 12 476 1 59 86 2,150 2,585 — 1 17 47 60
Missouri 6 7 22 342 453 101 198 266 7,916 7,988 — 1 5 34 31
Nebraska§ 5 2 8 101 99 11 27 57 1,140 1,083 — 0 2 13 7
North Dakota 2 0 16 18 16 1 2 7 76 110 — 0 2 2 5
South Dakota — 1 6 68 76 5 6 11 205 295 — 0 0 — —
S. Atlantic 51 56 106 2,194 2,122 944 1,590 3,209 60,948 69,432 4 11 34 459 441
Delaware — 1 6 34 35 6 26 43 1,015 1,160 — 0 3 6 1
District of Columbia — 0 7 34 53 — 47 72 1,768 1,372 — 0 2 3 4
Florida 34 24 47 1,017 845 480 472 717 18,769 19,122 2 3 8 128 133
Georgia 7 10 33 461 509 1 293 2,068 7,933 13,890 1 2 7 94 91
Maryland§ 5 4 17 193 186 98 118 227 4,836 5,672 — 1 6 65 64
North Carolina — 0 0 — — — 282 675 10,411 13,820 — 1 9 46 46
South Carolina§ 4 2 8 79 83 267 206 1,361 10,769 8,418 1 1 4 40 29
Virginia§ — 9 19 338 388 86 122 222 4,728 5,251 — 1 22 53 54
West Virginia 1 0 21 38 23 6 18 36 719 727 — 0 6 24 19
E.S. Central 5 10 23 406 350 343 560 752 21,695 24,465 — 2 9 98 95
Alabama§ — 4 16 175 167 — 153 242 5,483 8,626 — 0 3 20 20
Kentucky N 0 0 N N 27 54 268 2,495 2,305 — 0 1 2 5
Mississippi N 0 0 N N 148 141 310 5,873 5,864 — 0 1 7 12
Tennessee§ 5 5 16 231 183 168 193 261 7,844 7,670 — 2 6 69 58
W.S. Central 13 7 55 287 270 710 979 1,177 39,513 40,188 — 2 34 81 73
Arkansas§ 7 2 13 98 100 106 78 120 3,150 3,392 — 0 2 8 8
Louisiana — 1 9 74 70 111 220 384 8,720 8,646 — 0 2 6 18
Oklahoma 6 3 42 115 100 121 101 235 4,044 3,596 — 1 29 61 40
Texas§ N 0 0 N N 372 575 731 23,599 24,554 — 0 3 6 7
Mountain 41 30 63 1,258 1,353 20 250 374 9,441 12,107 5 4 12 202 174
Arizona 1 3 11 152 134 14 104 206 3,437 4,362 5 1 6 77 74
Colorado — 8 24 368 452 — 53 93 1,945 2,945 — 1 4 45 43
Idaho§ 7 3 12 139 151 6 4 20 215 132 — 0 1 5 5
Montana§ 4 2 8 87 83 — 1 8 50 158 — 0 1 2 —
Nevada§ 1 2 8 89 96 — 46 87 1,781 2,307 — 0 2 9 11
New Mexico§ — 2 6 79 66 — 30 58 1,333 1,425 — 1 4 32 24
Utah 28 6 32 313 341 — 17 34 618 674 — 0 3 29 14
Wyoming§ — 1 4 31 30 — 2 5 62 104 — 0 1 3 3
Pacific 82 60 558 2,545 2,206 334 721 875 28,452 32,831 — 3 16 103 87
Alaska 2 1 9 59 84 8 10 27 387 487 — 0 2 10 10
California 40 43 93 1,697 1,755 282 610 734 24,637 27,101 — 0 10 33 25
Hawaii — 1 4 53 44 1 11 22 490 776 — 0 2 9 14
Oregon§ 12 8 15 345 323 40 23 63 846 1,144 — 1 6 49 38
Washington 28 6 449 391 — 3 59 142 2,092 3,323 — 0 5 2 —
American Samoa U 0 0 U U U 0 2 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam — 0 0 — — — 1 38 74 89 — 0 0 — 1
Puerto Rico — 5 15 165 195 3 6 23 272 245 — 0 1 2 3
U.S. Virgin Islands U 0 0 U U U 1 3 U U U 0 0 U U
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Data for acute hepatitis C, viral are available in Table I.
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
                                          Hepatitis (viral, acute), by type†
A B Legionellosis
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 26 54 201 2,168 2,785 33 78 405 3,023 3,436 30 44 106 1,706 2,106
New England 1 2 6 97 156 — 2 5 55 96 3 2 12 96 150
Connecticut 1 0 3 17 34 — 0 5 23 39 1 0 5 31 40
Maine§ — 0 1 3 8 — 0 2 9 20 — 0 1 4 8
Massachusetts — 1 4 46 74 — 0 1 4 18 — 0 3 15 61
New Hampshire — 0 3 12 21 — 0 1 5 8 — 0 2 7 13
Rhode Island§ — 0 2 11 11 — 0 3 13 9 2 0 6 31 21
Vermont§ — 0 1 8 8 — 0 1 1 2 — 0 2 8 7
Mid. Atlantic 3 8 17 320 315 1 8 21 343 423 4 12 52 525 764
New Jersey — 2 5 72 92 — 1 8 64 136 — 1 10 66 100
New York (Upstate) 3 1 11 61 68 1 2 13 76 49 4 4 30 168 260
New York City — 3 7 122 103 — 1 6 74 101 — 2 8 78 149
Pennsylvania — 1 5 65 52 — 3 8 129 137 — 4 21 213 255
E.N. Central 5 6 13 224 287 9 9 23 345 404 6 9 27 391 470
Illinois — 2 5 79 89 — 2 6 96 114 — 1 6 56 103
Indiana 4 0 7 26 21 5 0 21 46 44 — 1 6 43 36
Michigan 1 1 8 59 95 — 2 8 85 117 2 2 10 116 117
Ohio — 1 4 53 45 4 2 7 106 100 4 3 17 168 178
Wisconsin — 0 3 7 37 — 0 3 12 29 — 0 3 8 36
W.N. Central 2 2 18 132 108 — 2 15 101 112 5 1 9 77 61
Iowa — 1 4 35 9 — 0 3 17 19 — 0 1 8 10
Kansas — 0 1 3 25 — 0 2 7 10 — 0 1 2 7
Minnesota — 0 17 56 9 — 0 13 17 14 4 0 6 21 12
Missouri 1 0 2 21 39 — 1 5 47 52 — 1 3 33 19
Nebraska§ 1 0 2 12 17 — 0 3 9 12 1 0 1 9 8
North Dakota — 0 3 — — — 0 1 — — — 0 1 — —
South Dakota — 0 1 5 9 — 0 1 4 5 — 0 1 4 5
S. Atlantic 9 10 21 410 435 7 18 56 764 954 6 7 25 288 350
Delaware — 0 1 7 11 — 0 3 15 37 — 0 2 6 9
District of Columbia — 0 5 14 6 — 0 2 1 5 — 0 4 1 19
Florida 6 3 11 128 174 6 7 14 270 331 3 2 10 122 129
Georgia — 1 4 58 46 — 2 7 91 165 — 0 2 18 26
Maryland§ 2 1 5 62 54 — 2 6 88 125 2 1 6 53 78
North Carolina 1 0 11 49 66 1 0 16 108 123 1 1 4 36 29
South Carolina§ — 0 4 15 21 — 1 5 51 72 — 0 2 14 4
Virginia§ — 1 5 69 52 — 3 8 102 50 — 1 4 30 46
West Virginia — 0 2 8 5 — 0 23 38 46 — 0 4 8 10
E.S. Central — 2 5 86 107 2 6 17 268 255 2 2 6 75 82
Alabama§ — 0 3 15 12 — 2 10 92 72 — 0 1 7 9
Kentucky — 0 2 18 31 1 1 7 56 60 1 1 6 39 31
Mississippi — 0 4 8 7 — 0 8 17 9 — 0 1 — 3
Tennessee§ — 1 5 45 57 1 3 8 103 114 1 1 4 29 39
W.S. Central — 5 43 180 290 8 18 169 619 688 2 2 16 86 56
Arkansas§ — 0 2 10 43 — 1 7 49 60 — 0 3 7 4
Louisiana — 1 3 24 25 — 1 4 62 49 — 0 1 3 10
Oklahoma — 0 8 11 6 5 1 24 46 53 — 0 6 5 1
Texas§ — 3 39 135 216 3 13 135 462 526 2 1 13 71 41
Mountain 1 5 15 205 223 2 3 7 137 112 1 2 5 75 101
Arizona — 3 11 146 132 — 1 4 48 — — 0 3 25 32
Colorado — 0 3 20 35 — 0 2 21 30 — 0 2 14 23
Idaho§ — 0 1 4 9 — 0 1 11 11 — 0 1 5 11
Montana§ — 0 2 9 9 — 0 3 — — — 0 1 3 5
Nevada§ — 0 2 9 11 — 1 3 29 30 — 0 2 7 7
New Mexico§ — 0 2 9 12 — 0 2 10 21 — 0 2 8 5
Utah — 0 1 5 13 2 0 4 16 20 1 0 2 10 18
Wyoming§ 1 0 1 3 2 — 0 1 2 — — 0 1 3 —
Pacific 5 12 92 514 864 4 10 106 391 392 1 2 11 93 72
Alaska 1 0 1 4 1 1 0 3 5 5 — 0 1 — —
California 4 10 40 445 819 2 7 31 288 318 1 1 11 67 72
Hawaii — 0 2 4 10 — 0 2 5 7 — 0 1 1 —
Oregon§ — 1 2 23 34 1 1 5 52 62 — 0 1 8 —
Washington — 0 52 38 — — 0 74 41 — — 0 3 17 —
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 1 10 45 50 — 1 9 44 50 — 0 2 3 1
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
Meningococcal disease, invasive†
Lyme disease Malaria All serogroups
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
United States 120 261 1,143 15,201 16,126 9 21 105 828 1,137 7 20 87 806 900
New England 29 38 287 2,826 3,795 — 1 5 37 45 1 1 3 34 38
Connecticut 15 11 214 1,512 1,561 — 0 3 1 10 — 0 1 6 9
Maine§ 13 3 53 317 196 — 0 2 6 4 1 0 3 6 4
Massachusetts — 2 20 64 1,370 — 0 3 21 22 — 0 2 18 19
New Hampshire — 6 78 670 577 — 0 4 7 8 — 0 1 — 4
Rhode Island§ — 0 93 151 1 — 0 1 — — — 0 1 1 —
Vermont§ 1 1 13 112 90 — 0 2 2 1 — 0 1 3 2
Mid. Atlantic 66 121 589 7,878 8,303 1 5 12 198 298 1 3 8 111 136
New Jersey — 26 134 1,725 2,202 — 0 3 — 78 — 0 2 13 18
New York (Upstate) 66 52 426 2,724 3,006 1 1 5 55 36 — 1 3 29 31
New York City — 1 19 122 271 — 3 7 112 143 1 0 4 26 51
Pennsylvania — 39 281 3,307 2,824 — 1 3 31 41 — 1 5 43 36
E.N. Central — 8 104 964 1,625 — 2 8 86 136 2 3 9 106 140
Illinois — 1 12 111 106 — 1 6 36 67 — 0 3 26 37
Indiana — 0 7 40 20 — 0 2 9 11 1 0 4 22 21
Michigan — 1 5 49 47 — 0 2 14 17 1 0 3 21 24
Ohio — 0 3 15 40 — 0 2 18 27 — 1 3 28 39
Wisconsin — 5 91 749 1,412 — 0 2 9 14 — 0 3 9 19
W.N. Central 1 5 195 343 507 — 0 12 28 33 1 1 5 50 54
Iowa — 1 11 93 92 — 0 1 3 1 — 0 3 11 15
Kansas — 0 2 9 4 — 0 1 2 7 — 0 1 1 4
Minnesota 1 1 188 209 396 — 0 12 11 14 1 0 3 16 12
Missouri — 0 6 25 5 — 0 1 5 6 — 0 3 13 13
Nebraska§ — 0 1 5 9 — 0 1 6 3 — 0 2 4 6
North Dakota — 0 7 2 — — 0 1 — 1 — 0 3 2 1
South Dakota — 0 0 — 1 — 0 1 1 1 — 0 1 3 3
S. Atlantic 20 52 169 2,945 1,748 1 4 13 197 284 1 3 11 140 156
Delaware 5 11 34 601 421 — 0 1 4 5 — 0 1 1 4
District of Columbia — 0 7 13 41 — 0 2 3 3 — 0 1 — 1
Florida 3 1 11 76 19 1 1 7 48 49 — 1 7 53 60
Georgia — 0 1 1 7 — 0 5 29 79 — 0 5 21 14
Maryland§ 12 25 109 1,519 988 — 1 5 48 66 — 0 2 20 13
North Carolina — 0 8 40 25 — 0 4 18 25 1 0 6 16 24
South Carolina§ — 0 2 22 18 — 0 1 6 9 — 0 2 14 18
Virginia§ — 11 60 616 217 — 1 4 39 46 — 0 2 13 16
West Virginia — 0 14 57 12 — 0 1 2 2 — 0 2 2 6
E.S. Central — 1 5 43 30 2 0 3 30 23 — 1 4 40 33
Alabama§ — 0 3 10 7 — 0 1 5 9 — 0 2 7 5
Kentucky — 0 2 4 7 — 0 1 7 3 — 0 2 9 7
Mississippi — 0 0 — 3 — 0 1 2 6 — 0 4 9 4
Tennessee§ — 0 4 29 13 2 0 2 16 5 — 0 2 15 17
W.S. Central 1 1 6 53 18 — 1 29 70 86 1 1 15 81 83
Arkansas§ — 0 1 1 — — 0 0 — 4 — 0 2 9 10
Louisiana — 0 1 2 — — 0 2 14 6 — 0 4 25 33
Oklahoma — 0 0 — — — 0 3 5 7 — 0 4 15 8
Texas§ 1 1 6 50 18 — 1 25 51 69 1 0 11 32 32
Mountain — 0 4 34 25 — 1 6 48 61 — 1 4 52 60
Arizona — 0 1 2 9 — 0 3 11 20 — 0 2 12 14
Colorado — 0 1 2 — — 0 2 16 13 — 0 2 17 20
Idaho§ — 0 2 7 5 — 0 2 2 1 — 0 1 3 3
Montana§ — 0 2 4 — — 0 1 3 2 — 0 1 2 4
Nevada§ — 0 2 7 3 — 0 1 2 3 — 0 1 4 5
New Mexico§ — 0 1 4 3 — 0 1 3 5 — 0 1 2 4
Utah — 0 2 5 4 — 0 3 11 17 — 0 2 10 6
Wyoming§ — 0 1 3 1 — 0 0 — — — 0 1 2 4
Pacific 3 2 16 115 75 5 3 45 134 171 — 4 48 192 200
Alaska — 0 1 5 3 — 0 1 2 23 — 0 1 1 3
California 3 2 9 106 66 5 2 7 95 130 — 3 10 138 153
Hawaii N 0 0 N N — 0 1 2 8 — 0 2 8 8
Oregon§ — 0 1 3 6 — 0 3 13 10 — 0 3 27 36
Washington — 0 8 1 — — 0 43 22 — — 0 43 18 —
American Samoa U 0 0 U U U 0 0 U U U 0 0 — —
C.N.M.I. U — — U U U — — U U U — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico N 0 0 N N — 0 1 3 1 — 0 1 6 6
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 — —
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C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
Pertussis Rabies, animal Rocky Mountain spotted fever
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 60 172 1,479 6,690 11,136 66 94 148 3,927 4,538 20 31 211 1,632 1,786
New England 3 29 77 1,050 1,367 16 12 22 481 373 — 0 10 2 11
Connecticut — 2 5 49 91 5 4 10 189 165 — 0 0 — —
Maine† 1 2 14 63 108 5 2 7 72 94 — 0 0 — —
Massachusetts — 24 46 845 856 — 0 0 — — — 0 1 2 10
New Hampshire — 1 9 48 175 — 1 4 41 35 — 0 0 — 1
Rhode Island† — 0 31 16 45 2 0 4 35 25 — 0 9 — —
Vermont† 2 0 9 29 92 4 3 13 144 54 — 0 0 — —
Mid. Atlantic 10 24 155 909 1,457 — 13 44 605 441 — 1 6 49 79
New Jersey — 3 11 116 249 — 0 0 — — — 0 2 6 36
New York (Upstate) 10 13 146 478 648 — — — — — — 0 1 3 —
New York City — 2 6 90 77 — 1 5 33 29 — 0 3 19 22
Pennsylvania — 7 15 225 483 — 12 44 572 412 — 0 3 21 21
E.N. Central 6 31 79 1,172 1,730 6 4 48 354 143 — 1 4 40 57
Illinois — 3 23 109 432 1 1 15 108 46 — 0 3 23 24
Indiana — 0 45 47 181 1 0 1 11 11 — 0 2 5 6
Michigan — 7 29 236 467 2 1 27 166 41 — 0 1 3 3
Ohio 6 16 54 581 475 2 0 11 69 45 — 0 2 9 23
Wisconsin — 3 24 199 175 — 0 0 — — — 0 0 — 1
W.N. Central 3 13 151 496 1,039 — 5 13 226 271 2 4 31 335 184
Iowa — 3 16 113 250 — 0 3 31 54 — 0 4 13 5
Kansas — 3 13 104 239 — 2 8 95 67 — 0 1 1 1
Minnesota — 0 119 111 161 — 0 5 27 36 — 0 1 1 3
Missouri — 2 9 63 264 — 0 3 39 63 2 3 25 305 152
Nebraska† 3 1 12 51 80 — 0 0 — — — 0 2 11 23
North Dakota — 0 18 4 25 — 0 6 16 16 — 0 0 — —
South Dakota — 1 6 50 20 — 0 2 18 35 — 0 1 4 —
S. Atlantic 9 18 163 754 880 36 40 76 1,699 1,903 14 13 111 801 972
Delaware — 0 2 10 3 — 0 0 — — — 0 2 12 21
District of Columbia — 0 1 2 6 — 0 0 — — — 0 1 1 1
Florida — 4 18 186 176 — 0 29 101 176 2 0 4 19 10
Georgia — 1 5 25 79 — 4 34 200 220 — 0 5 30 48
Maryland† 2 2 8 87 117 — 7 18 285 349 2 1 7 51 70
North Carolina 5 2 112 255 155 16 9 19 412 426 10 5 96 519 702
South Carolina† 2 2 9 65 148 — 1 11 46 145 — 1 7 60 34
Virginia† — 2 17 97 157 11 13 31 592 499 — 2 10 104 83
West Virginia — 0 19 27 39 9 0 8 63 88 — 0 3 5 3
E.S. Central 1 5 28 301 293 — 3 11 133 208 2 4 16 210 331
Alabama† — 1 18 63 73 — 0 5 — 69 — 1 8 61 81
Kentucky — 0 1 5 56 — 0 3 18 25 — 0 2 5 3
Mississippi — 1 26 162 32 — 0 1 1 4 — 0 2 9 5
Tennessee† 1 2 7 71 132 — 3 9 114 110 2 2 10 135 242
W.S. Central 7 20 226 732 667 1 2 32 71 797 2 1 168 158 105
Arkansas† — 2 17 119 73 1 0 5 26 26 2 0 53 82 46
Louisiana — 0 1 14 24 — 0 1 — 5 — 0 1 2 4
Oklahoma — 0 36 6 18 — 0 22 45 52 — 0 108 45 28
Texas† 7 16 174 593 552 — 0 26 — 714 — 0 7 29 27
Mountain 21 22 61 844 2,143 1 3 14 183 190 — 0 4 29 45
Arizona — 4 13 171 444 — 2 12 127 125 — 0 1 7 11
Colorado — 6 17 218 643 — 0 0 — — — 0 2 3 4
Idaho† — 1 5 34 80 — 0 0 — 24 — 0 1 4 14
Montana† — 0 7 33 103 — 0 3 15 14 — 0 1 1 2
Nevada† — 0 5 11 65 — 0 1 2 5 — 0 0 — —
New Mexico† — 2 8 55 99 — 0 2 8 8 — 0 1 4 7
Utah 21 7 47 303 640 1 0 2 14 9 — 0 0 — —
Wyoming† — 0 5 19 69 — 0 4 17 5 — 0 2 10 7
Pacific — 12 547 432 1,560 6 4 10 175 212 — 0 3 8 2
Alaska — 0 8 41 81 1 0 6 37 15 N 0 0 N N
California — 3 167 113 1,304 4 2 8 127 174 — 0 3 6 —
Hawaii — 0 2 18 84 N 0 0 N N N 0 0 N N
Oregon† — 2 11 89 91 1 0 3 11 23 — 0 1 2 2
Washington — 2 377 171 — — 0 0 — — N 0 0 N N
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam — 0 2 — 59 — 0 0 — — N 0 0 N N
Puerto Rico — 0 1 — 1 — 1 5 37 68 N 0 0 N N
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
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U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 637 861 2,338 32,760 34,538 81 80 336 3,365 3,250 266 331 1,287 12,144 10,522
New England 7 34 365 1,824 1,927 — 3 83 248 249 8 4 37 205 243
Connecticut — 0 350 350 503 — 0 77 77 75 — 0 34 34 67
Maine§ 3 2 14 103 104 — 1 4 33 36 — 0 5 14 4
Massachusetts — 23 57 1,096 1,000 — 2 10 109 88 — 3 8 136 150
New Hampshire — 3 10 130 184 — 0 3 14 24 — 0 2 5 4
Rhode Island§ 4 1 20 80 77 — 0 2 6 8 8 0 3 13 12
Vermont§ — 2 5 65 59 — 0 1 9 18 — 0 1 3 6
Mid. Atlantic 31 98 176 3,975 4,384 5 7 63 320 385 4 11 47 553 763
New Jersey — 11 25 321 933 — 1 20 27 98 — 2 9 91 270
New York (Upstate) 23 29 112 1,159 1,019 5 3 15 162 136 3 3 42 116 192
New York City 8 24 50 1,107 1,049 — 0 4 28 40 1 5 10 209 227
Pennsylvania — 32 69 1,388 1,383 — 3 47 103 111 — 1 21 137 74
E.N. Central 49 104 219 4,440 4,595 22 9 28 459 573 25 33 128 1,707 1,103
Illinois — 30 153 1,342 1,296 — 1 6 37 95 — 10 32 374 513
Indiana 20 14 54 579 724 13 1 9 78 73 5 2 11 88 118
Michigan 4 16 35 711 822 2 1 6 72 77 — 1 7 54 133
Ohio 23 26 65 1,081 1,011 6 3 11 138 150 17 9 104 1,000 132
Wisconsin 2 17 50 727 742 1 3 8 134 178 3 3 13 191 207
W.N. Central 47 49 101 2,159 2,140 21 11 45 605 559 24 37 156 1,516 1,384
Iowa 2 8 19 367 381 — 2 38 139 112 — 2 14 70 92
Kansas — 6 20 274 301 — 0 4 37 21 — 0 3 20 121
Minnesota 20 13 44 557 547 13 4 17 208 170 10 5 24 200 142
Missouri 18 15 26 588 607 5 2 12 114 142 13 18 72 1,094 577
Nebraska§ 6 4 12 205 160 2 1 6 68 69 1 0 7 20 113
North Dakota 1 0 23 35 22 1 0 12 2 5 — 0 127 5 63
South Dakota — 3 11 133 122 — 0 5 37 40 — 1 30 107 276
S. Atlantic 327 222 421 8,853 8,906 7 15 37 544 498 81 88 174 3,625 2,400
Delaware 1 2 8 123 131 — 0 3 13 7 — 0 2 10 8
District of Columbia — 0 4 16 51 — 0 1 1 2 — 0 5 4 14
Florida 169 85 176 3,511 3,613 1 2 8 113 73 32 45 76 1,877 1,110
Georgia 48 33 70 1,541 1,474 — 1 8 76 70 18 32 94 1,303 888
Maryland§ 12 15 37 693 616 3 2 5 77 98 1 2 9 87 98
North Carolina 69 29 110 1,243 1,286 2 2 24 117 92 — 0 14 71 127
South Carolina§ 24 17 51 816 834 — 0 3 15 11 20 2 8 126 76
Virginia§ — 19 39 757 798 — 3 8 115 133 — 3 11 123 75
West Virginia 4 3 31 153 103 1 0 5 17 12 10 0 7 24 4
E.S. Central 31 54 134 2,307 2,243 7 4 26 253 254 26 26 91 1,472 560
Alabama§ — 14 78 624 599 — 0 19 55 28 — 10 67 453 169
Kentucky 14 9 22 454 370 3 1 10 92 81 21 3 33 377 189
Mississippi — 12 101 580 655 — 0 2 4 10 — 5 76 486 80
Tennessee§ 17 17 34 649 619 4 2 10 102 135 5 3 14 156 122
W.S. Central 40 83 595 3,143 4,034 1 3 73 140 169 56 39 655 1,378 1,493
Arkansas§ 6 14 46 590 742 — 1 5 27 38 2 2 10 72 81
Louisiana — 16 41 573 861 — 0 2 3 13 — 8 22 349 200
Oklahoma 34 8 103 499 403 1 0 17 17 18 2 3 63 99 104
Texas§ — 43 470 1,481 2,028 — 2 68 93 100 52 24 580 858 1,108
Mountain 23 48 90 1,978 2,115 8 8 31 395 453 19 19 66 739 1,090
Arizona 4 17 44 728 693 1 2 8 87 85 7 11 37 434 552
Colorado — 10 22 429 516 — 1 9 64 96 — 2 9 88 182
Idaho§ 3 3 7 105 143 3 1 16 112 79 1 0 2 9 14
Montana§ — 1 6 74 111 — 0 0 — — — 1 13 19 24
Nevada§ 3 4 10 145 180 — 0 5 18 30 9 0 9 47 103
New Mexico§ — 5 13 205 208 — 1 3 32 40 — 2 7 82 151
Utah 12 4 18 233 227 4 1 9 82 105 2 1 5 29 54
Wyoming§ 1 1 4 59 37 — 0 1 — 18 — 0 19 31 10
Pacific 82 103 890 4,081 4,194 10 6 164 401 110 23 25 256 949 1,486
Alaska 1 1 5 65 65 N 0 0 N N — 0 2 7 7
California 68 81 260 3,044 3,597 6 3 34 206 N 18 21 84 772 1,327
Hawaii — 5 16 208 190 1 0 4 19 13 — 0 2 21 41
Oregon§ — 7 15 249 340 — 1 11 70 97 — 1 6 61 111
Washington 13 10 625 515 2 3 1 162 106 — 5 1 170 88 —
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam — 0 0 — — N 0 0 N N — 0 0 — —
Puerto Rico — 13 66 446 450 — 0 0 — — — 0 4 18 33
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
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C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by S. pneumoniae, which is susceptible or for which susceptibility testing is not available
(NNDSS event code 11717).
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
Streptococcus pneumoniae, invasive disease, nondrug resistant†
Streptococcal disease, invasive, group A Age <5 years
Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006
United States 22 97 261 4,028 4,326 15 30 108 1,208 1,031
New England 1 6 28 326 291 1 2 11 94 93
Connecticut — 0 23 99 77 — 0 6 12 27
Maine§ — 0 3 22 16 — 0 1 2 —
Massachusetts — 3 12 153 146 1 2 6 63 55
New Hampshire — 0 4 31 34 — 0 2 7 7
Rhode Island§ 1 0 12 5 6 — 0 2 8 4
Vermont§ — 0 2 16 12 — 0 1 2 —
Mid. Atlantic 2 17 41 743 781 4 4 27 194 141
New Jersey — 3 10 107 126 — 1 4 25 52
New York (Upstate) 2 5 27 245 251 4 2 15 86 70
New York City — 4 13 176 139 — 1 25 83 19
Pennsylvania — 5 11 215 265 N 0 0 N N
E.N. Central 5 17 33 683 827 2 5 14 182 271
Illinois — 5 13 185 251 — 1 6 47 68
Indiana 1 2 17 110 99 — 0 10 16 47
Michigan — 4 10 164 174 — 1 4 59 63
Ohio 4 4 14 196 206 2 1 7 51 53
Wisconsin — 0 6 28 97 — 0 2 9 40
W.N. Central 1 5 32 275 291 4 2 8 90 87
Iowa — 0 0 — — — 0 0 — —
Kansas — 0 3 28 47 — 0 1 1 11
Minnesota — 0 29 137 136 3 1 6 61 54
Missouri — 2 6 67 62 1 0 2 17 11
Nebraska§ — 0 3 23 26 — 0 2 10 8
North Dakota 1 0 2 13 10 — 0 2 1 3
South Dakota — 0 2 7 10 — 0 0 — —
S. Atlantic 7 22 52 1,014 969 1 4 14 222 63
Delaware — 0 1 9 10 — 0 0 — —
District of Columbia — 0 3 8 13 — 0 1 — 1
Florida 5 6 16 253 238 — 1 5 52 —
Georgia 2 5 13 199 201 — 0 5 44 —
Maryland§ — 4 10 174 180 1 1 6 50 51
North Carolina — 1 22 141 138 — 0 0 — —
South Carolina§ — 1 7 83 55 — 0 4 38 —
Virginia§ — 2 11 124 109 — 0 4 31 —
West Virginia — 0 3 23 25 — 0 4 7 11
E.S. Central — 4 13 171 172 — 1 6 74 16
Alabama§ N 0 0 N N N 0 0 N N
Kentucky — 1 3 33 39 — 0 0 — —
Mississippi N 0 0 N N — 0 2 3 16
Tennessee§ — 3 13 138 133 — 1 6 71 —
W.S. Central 2 6 90 254 330 3 4 43 175 177
Arkansas§ — 0 2 17 23 — 0 2 10 18
Louisiana — 0 4 16 16 — 0 4 27 20
Oklahoma — 1 23 60 85 1 1 13 41 43
Texas§ 2 3 64 161 206 2 1 27 97 96
Mountain 3 9 23 449 567 — 4 12 151 163
Arizona 1 4 11 176 295 — 2 7 89 91
Colorado — 3 9 127 98 — 1 4 36 43
Idaho§ — 0 2 15 8 — 0 1 2 1
Montana§ N 0 0 N N N 0 0 N N
Nevada§ — 0 1 2 — — 0 1 1 2
New Mexico§ — 1 4 48 109 — 0 4 19 26
Utah 2 2 7 76 54 — 0 2 4 —
Wyoming§ — 0 1 5 3 — 0 0 — —
Pacific 1 3 9 113 98 — 0 4 26 20
Alaska — 0 3 30 N — 0 2 24 —
California N 0 0 N N N 0 0 N N
Hawaii 1 2 9 83 98 — 0 2 2 20
Oregon§ N 0 0 N N N 0 0 N N
Washington N 0 0 N N N 0 0 N N
American Samoa U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U
Guam — 0 0 — — N 0 0 N N
Puerto Rico — 0 0 — — N 0 0 N N
U.S. Virgin Islands U 0 0 U U U 0 0 U U
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U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.
†
Includes cases of invasive pneumococcal disease caused by drug-resistant S. pneumoniae (DRSP) (NNDSS event code 11720).
§
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
Streptococcus pneumoniae, invasive disease, drug resistant†
All ages Age <5 years Syphilis, primary and secondary
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 17 48 256 1,824 1,930 6 9 35 335 309 99 203 310 8,023 7,478
New England — 2 12 86 101 — 0 3 10 3 2 5 13 202 162
Connecticut — 2 5 50 76 — 0 2 4 — — 0 10 25 34
Maine§ — 0 2 9 6 — 0 2 1 1 1 0 2 9 8
Massachusetts — 0 0 — — — 0 0 — — 1 3 8 123 99
New Hampshire — 0 0 — — — 0 0 — — — 0 3 22 10
Rhode Island§ — 0 4 14 9 — 0 1 3 — — 0 5 21 9
Vermont§ — 0 2 13 10 — 0 1 2 2 — 0 1 2 2
Mid. Atlantic — 2 9 99 113 — 0 5 21 15 16 29 44 1,203 897
New Jersey — 0 0 — — — 0 0 — — 5 4 8 160 135
New York (Upstate) — 1 5 35 36 — 0 4 7 7 3 3 14 111 121
New York City — 0 0 — — — 0 0 — — 5 17 34 737 426
Pennsylvania — 2 6 64 77 — 0 2 14 8 3 5 10 195 215
E.N. Central 5 10 40 427 404 2 2 7 59 66 4 15 27 621 699
Illinois — 0 4 15 21 — 0 1 2 6 — 7 13 282 339
Indiana 3 2 31 113 107 1 0 5 19 17 1 1 6 43 72
Michigan — 0 1 2 15 — 0 1 1 2 — 2 9 93 88
Ohio 2 5 38 297 261 1 1 5 37 41 3 4 10 157 145
Wisconsin N 0 0 N N — 0 0 — — — 1 4 46 55
W.N. Central — 1 124 116 85 — 0 15 9 13 2 6 13 274 226
Iowa — 0 0 — — — 0 0 — — — 0 3 11 15
Kansas — 0 11 63 — — 0 2 5 — — 0 3 16 18
Minnesota — 0 123 — 51 — 0 15 — 10 — 1 5 53 41
Missouri — 1 5 45 32 — 0 1 — 3 2 4 11 185 134
Nebraska§ — 0 1 2 1 — 0 0 — — — 0 2 2 5
North Dakota — 0 0 — — — 0 0 — — — 0 0 — 1
South Dakota — 0 3 6 1 — 0 1 4 — — 0 3 7 12
S. Atlantic 8 21 59 809 921 3 4 15 172 142 37 48 180 1,883 1,677
Delaware — 0 1 7 — — 0 1 2 — — 0 3 12 16
District of Columbia — 0 2 5 21 — 0 0 — 2 — 2 12 133 96
Florida 8 11 29 467 494 2 2 8 100 91 16 16 38 698 579
Georgia — 7 17 280 311 1 1 10 62 49 — 7 153 272 301
Maryland§ — 0 1 1 — — 0 0 — — 4 6 15 247 244
North Carolina — 0 0 — — — 0 0 — — 16 5 23 263 240
South Carolina§ — 0 0 — — — 0 0 — — 1 2 11 82 55
Virginia§ N 0 0 N N — 0 0 — — — 4 17 171 137
West Virginia — 1 17 49 95 — 0 1 8 — — 0 1 5 9
E.S. Central 4 3 9 128 158 1 0 3 28 28 7 17 30 679 559
Alabama§ N 0 0 N N — 0 0 — — — 6 16 267 255
Kentucky — 0 2 19 30 — 0 1 2 6 — 1 7 46 56
Mississippi — 0 2 — 22 — 0 0 — — 1 2 9 85 52
Tennessee§ 4 2 8 109 106 1 0 3 26 22 6 6 15 281 196
W.S. Central — 2 11 114 68 — 0 3 17 7 26 35 55 1,424 1,218
Arkansas§ — 0 1 1 10 — 0 0 — 2 2 1 10 96 60
Louisiana — 1 4 52 58 — 0 2 7 5 6 8 29 360 236
Oklahoma — 0 9 61 — — 0 2 10 — 2 1 4 44 57
Texas§ — 0 0 — — — 0 0 — — 16 21 39 924 865
Mountain — 1 5 45 80 — 0 3 16 35 — 7 19 270 399
Arizona — 0 0 — — — 0 0 — — — 3 12 104 150
Colorado — 0 0 — — — 0 0 — — — 1 5 31 58
Idaho§ N 0 0 N N — 0 0 — — — 0 1 1 3
Montana§ — 0 0 — — — 0 0 — — — 0 1 1 1
Nevada§ — 0 3 18 16 — 0 2 5 2 — 2 6 87 112
New Mexico§ — 0 0 — — — 0 0 — — — 1 7 37 61
Utah — 0 5 15 33 — 0 3 9 23 — 0 2 6 14
Wyoming§ — 0 2 12 31 — 0 1 2 10 — 0 1 3 —
Pacific — 0 0 — — — 0 1 3 — 5 38 57 1,467 1,641
Alaska — 0 0 — — — 0 0 — — 1 0 1 6 9
California N 0 0 N N — 0 0 — — 3 36 54 1,338 1,460
Hawaii — 0 0 — — — 0 1 3 — — 0 2 7 15
Oregon§ N 0 0 N N — 0 0 — — 1 0 6 14 15
Washington N 0 0 N N — 0 0 — — — 2 12 102 142
American Samoa U 0 0 U U U 0 1 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam N 0 0 N N — 0 0 — — — 0 1 3 —
Puerto Rico N 0 0 N N — 0 0 — — 4 3 10 123 114
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 13, 2007, and October 14, 2006
(41st Week)*
West Nile virus disease†
Varicella (chickenpox) Neuroinvasive Nonneuroinvasive§
Previous Previous Previous
Current 52 weeks  Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum.
* Incidence data for reporting year 2007 are provisional.†
Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data
for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.§
Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.¶
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
United States 374 796 2,813 27,405 35,203 — 1 122 951 1,465 3 2 283 2,071 2,730
New England 3 16 124 544 3,436 — 0 2 6 9 — 0 2 5 3
Connecticut — 0 76 2 1,272 — 0 2 3 7 — 0 1 1 2
Maine¶ — 0 7 — 188 — 0 0 — — — 0 0 — —
Massachusetts — 0 1 — 1,141 — 0 2 3 2 — 0 2 3 1
New Hampshire — 7 17 246 301 — 0 0 — — — 0 0 — —
Rhode Island¶ — 0 0 — — — 0 0 — — — 0 1 1 —
Vermont¶ 3 9 66 296 534 — 0 0 — — — 0 0 — —
Mid. Atlantic — 108 195 3,278 3,858 — 0 3 14 26 — 0 1 4 12
New Jersey N 0 0 N N — 0 1 1 2 — 0 0 — 3
New York (Upstate) N 0 0 N N — 0 0 — 8 — 0 0 — 4
New York City — 0 0 — — — 0 3 10 8 — 0 1 1 4
Pennsylvania — 108 195 3,278 3,858 — 0 1 3 8 — 0 1 3 1
E.N. Central 103 229 568 7,708 11,285 — 0 14 73 244 — 0 7 38 174
Illinois — 2 11 111 115 — 0 12 42 127 — 0 6 26 88
Indiana — 0 0 — — — 0 2 6 27 — 0 1 4 53
Michigan 36 97 258 3,123 3,445 — 0 5 12 43 — 0 0 — 12
Ohio 67 106 449 3,677 6,912 — 0 4 10 36 — 0 2 5 11
Wisconsin — 19 80 797 813 — 0 1 3 11 — 0 1 3 10
W.N. Central 17 32 136 1,304 1,393 — 0 40 230 222 — 0 110 680 479
Iowa N 0 0 N N — 0 4 10 22 — 0 3 13 15
Kansas — 9 52 439 263 — 0 3 11 17 — 0 7 26 13
Minnesota — 0 0 — — — 0 11 42 31 — 0 11 54 34
Missouri 17 15 78 719 1,025 — 0 9 52 50 — 0 1 9 10
Nebraska¶ N 0 0 N N — 0 5 18 44 — 0 15 117 215
North Dakota — 0 60 84 44 — 0 11 49 20 — 0 45 303 117
South Dakota — 1 15 62 61 — 0 9 48 38 — 0 32 158 75
S. Atlantic 86 100 239 4,003 3,549 — 0 11 34 17 — 0 6 30 13
Delaware — 1 4 37 61 — 0 1 1 — — 0 0 — —
District of Columbia — 0 8 14 34 — 0 0 — — — 0 1 — 1
Florida 28 21 76 990 N — 0 1 3 3 — 0 0 — —
Georgia N 0 0 N N — 0 8 22 2 — 0 4 22 6
Maryland¶ N 0 0 N N — 0 2 4 10 — 0 2 5 1
North Carolina — 0 0 — — — 0 1 — 1 — 0 0 — —
South Carolina¶ 40 21 72 851 915 — 0 2 2 — — 0 1 2 —
Virginia¶ — 28 190 1,201 1,342 — 0 1 2 — — 0 1 1 5
West Virginia 18 23 50 910 1,197 — 0 0 — 1 — 0 0 — —
E.S. Central — 5 571 383 28 — 0 11 59 116 — 0 13 76 95
Alabama¶ — 5 571 380 26 — 0 2 13 8 — 0 1 4 —
Kentucky N 0 0 N N — 0 1 3 5 — 0 0 — 1
Mississippi — 0 2 3 2 — 0 7 39 87 — 0 11 69 88
Tennessee¶ N 0 0 N N — 0 1 4 16 — 0 1 3 6
W.S. Central 119 155 1,640 8,116 9,489 — 0 23 148 366 — 0 12 64 229
Arkansas¶ 9 13 105 564 703 — 0 4 10 24 — 0 2 5 5
Louisiana — 1 11 99 191 — 0 1 1 89 — 0 1 1 85
Oklahoma — 0 0 — — — 0 10 48 26 — 0 7 38 20
Texas¶ 110 144 1,534 7,453 8,595 — 0 16 89 227 — 0 4 20 119
Mountain 46 55 131 2,039 2,165 — 0 35 240 379 — 1 139 956 1,465
Arizona — 0 0 — — — 0 7 28 54 — 0 11 34 67
Colorado — 22 62 813 1,175 — 0 17 95 66 — 0 65 449 278
Idaho¶ N 0 0 N N — 0 2 7 139 — 0 16 97 851
Montana¶ 1 5 40 305 N — 0 10 36 12 — 0 30 157 22
Nevada¶ — 0 1 1 9 — 0 1 2 34 — 0 3 9 90
New Mexico¶ — 5 37 302 317 — 0 8 36 3 — 0 6 21 5
Utah 45 14 73 600 628 — 0 8 21 56 — 0 7 26 102
Wyoming¶ — 0 11 18 36 — 0 4 15 15 — 0 34 163 50
Pacific — 0 9 30 — — 0 18 147 86 3 0 22 218 260
Alaska — 0 9 30 N — 0 0 — — — 0 0 — —
California — 0 0 — N — 0 18 143 79 3 0 19 200 195
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon¶ N 0 0 N N — 0 1 4 7 — 0 4 18 62
Washington N 0 0 N N — 0 0 — — — 0 0 — 3
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U — — U U U — — U U U — — U U
Guam 2 6 30 168 191 — 0 0 — — — 0 0 — —
Puerto Rico — 11 30 467 463 — 0 0 — — — 0 0 — —
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
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TABLE III. Deaths in 122 U.S. cities,* week ending October 13, 2007 (41st Week)
All causes, by age (years) All causes, by age (years)
All P&I† All P&I†
Reporting Area Ages >65 45-64 25-44 1-24 <1 Total Reporting Area Ages >65 45-64 25-44 1-24 <1 Total
U: Unavailable.     —:No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its
occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.
** Total includes unknown ages.
New England 512 347 117 25 12 11 43
Boston, MA 146 95 37 8 5 1 13
Bridgeport, CT 31 20 9 2 — — 4
Cambridge, MA 12 10 2 — — — 1
Fall River, MA 18 14 3 — 1 — —
Hartford, CT 46 28 11 1 2 4 3
Lowell, MA 22 17 5 — — — 4
Lynn, MA 6 4 1 1 — — 1
New Bedford, MA 20 13 4 1 1 1 1
New Haven, CT 52 36 9 4 1 2 6
Providence, RI 50 33 12 3 2 — 1
Somerville, MA 3 3 — — — — —
Springfield, MA 40 23 12 3 — 2 3
Waterbury, CT 20 17 3 — — — 2
Worcester, MA 46 34 9 2 — 1 4
Mid. Atlantic 2,021 1,397 443 114 31 35 79
Albany, NY 34 22 9 2 — 1 1
Allentown, PA 39 25 11 3 — — 1
Buffalo, NY 68 45 16 5 — 2 7
Camden, NJ 35 23 9 1 1 1 2
Elizabeth, NJ 22 19 2 — — 1 1
Erie, PA 47 35 10 1 — 1 3
Jersey City, NJ 29 15 10 4 — — 1
New York City, NY 995 727 197 50 11 9 30
Newark, NJ 38 16 12 8 — 2 2
Paterson, NJ 24 14 8 1 — 1 2
Philadelphia, PA 321 187 91 26 11 6 10
Pittsburgh, PA§ 34 22 1 3 2 6 —
Reading, PA 25 21 3 1 — — 1
Rochester, NY 115 80 25 3 4 3 12
Schenectady, NY 15 12 3 — — — —
Scranton, PA 23 20 3 — — — —
Syracuse, NY 79 57 19 1 — 2 3
Trenton, NJ 33 20 10 2 1 — 1
Utica, NY 18 15 1 1 1 — —
Yonkers, NY 27 22 3 2 — — 2
E.N. Central 1,784 1,168 396 143 50 27 107
Akron, OH 60 39 15 5 — 1 1
Canton, OH 33 22 7 2 1 1 3
Chicago, IL 230 137 64 21 6 2 19
Cincinnati, OH 72 45 16 9 1 1 11
Cleveland, OH 204 146 42 9 3 4 7
Columbus, OH 172 107 41 21 3 — 14
Dayton, OH 99 79 15 4 1 — 6
Detroit, MI 160 86 40 21 8 5 8
Evansville, IN 39 23 12 4 — — 2
Fort Wayne, IN 57 46 9 1 1 — 4
Gary, IN 15 6 4 1 2 2 —
Grand Rapids, MI 47 33 7 5 1 1 5
Indianapolis, IN 192 111 43 20 13 5 12
Lansing, MI 35 26 5 3 — 1 1
Milwaukee, WI 90 60 24 4 1 1 5
Peoria, IL 50 35 9 3 2 1 4
Rockford, IL 54 36 10 2 5 1 —
South Bend, IN 39 30 8 1 — — —
Toledo, OH 85 61 17 6 1 — 4
Youngstown, OH 51 40 8 1 1 1 1
W.N. Central 548 372 111 38 13 14 40
Des Moines, IA 100 80 16 3 — 1 11
Duluth, MN 24 16 6 — 2 — 2
Kansas City, KS 23 13 7 3 — — 3
Kansas City, MO 87 57 18 7 4 1 3
Lincoln, NE 47 35 8 3 1 — 6
Minneapolis, MN 70 37 19 10 — 4 8
Omaha, NE 66 41 15 3 3 4 3
St. Louis, MO 26 13 7 2 3 1 —
St. Paul, MN 36 32 2 2 — — 1
Wichita, KS 69 48 13 5 — 3 3
S. Atlantic 1,111 703 280 74 33 21 68
Atlanta, GA 85 52 19 8 5 1 5
Baltimore, MD 135 77 39 15 3 1 14
Charlotte, NC 134 84 37 9 2 2 9
Jacksonville, FL 175 107 45 17 5 1 16
Miami, FL 103 71 26 3 1 2 5
Norfolk, VA 53 33 12 3 2 3 3
Richmond, VA 61 33 21 3 — 4 1
Savannah, GA 56 38 11 3 3 1 3
St. Petersburg, FL 96 67 22 3 4 — 5
Tampa, FL 140 94 29 9 4 4 6
Washington, D.C. 62 39 16 1 4 2 1
Wilmington, DE 11 8 3 — — — —
E.S. Central 842 533 198 80 16 15 58
Birmingham, AL 169 103 35 17 8 6 10
Chattanooga, TN 86 59 17 9 1 — 12
Knoxville, TN 95 65 22 7 — 1 2
Lexington, KY 70 48 18 4 — — 3
Memphis, TN 138 89 38 10 1 — 12
Mobile, AL 88 51 22 13 1 1 5
Montgomery, AL 48 27 15 5 — 1 5
Nashville, TN 148 91 31 15 5 6 9
W.S. Central 1,258 800 278 111 42 27 83
Austin, TX 95 59 20 9 4 3 7
Baton Rouge, LA 30 9 9 2 10 — 4
Corpus Christi, TX 54 35 14 5 — — 4
Dallas, TX 183 111 49 11 4 8 10
El Paso, TX 94 69 15 7 1 2 6
Fort Worth, TX 88 58 21 4 3 2 4
Houston, TX 260 148 66 31 10 5 22
Little Rock, AR 77 49 15 8 2 3 3
New Orleans, LA¶ U U U U U U U
San Antonio, TX 204 140 34 23 6 1 10
Shreveport, LA 68 41 17 6 1 3 8
Tulsa, OK 105 81 18 5 1 — 5
Mountain 958 623 211 70 25 29 52
Albuquerque, NM 119 76 27 11 2 3 5
Boise, ID 33 23 7 2 1 — 4
Colorado Springs, CO 65 40 14 10 — 1 1
Denver, CO 78 52 13 4 5 4 5
Las Vegas, NV 190 120 51 13 3 3 16
Ogden, UT 31 26 5 — — — 1
Phoenix, AZ 167 99 44 11 2 11 9
Pueblo, CO 23 17 4 2 — — —
Salt Lake City, UT 124 72 31 10 7 4 6
Tucson, AZ 128 98 15 7 5 3 5
Pacific 1,273 858 275 80 35 24 84
Berkeley, CA 11 8 2 1 — — —
Fresno, CA 86 65 13 6 2 — 4
Glendale, CA U U U U U U U
Honolulu, HI 53 39 8 4 2 — 3
Long Beach, CA 67 45 15 4 2 1 10
Los Angeles, CA U U U U U U U
Pasadena, CA 21 16 4 — 1 — 1
Portland, OR 137 89 35 6 2 4 10
Sacramento, CA 176 116 37 8 8 7 12
San Diego, CA 145 90 32 11 7 5 12
San Francisco, CA 108 68 19 15 5 1 12
San Jose, CA 182 128 40 7 4 3 10
Santa Cruz, CA 18 15 2 1 — — 1
Seattle, WA 110 68 29 9 2 2 4
Spokane, WA 54 44 9 1 — — 2
Tacoma, WA 105 67 30 7 — 1 3
Total 10,307** 6,801 2,309 735 257 203 614
1098 MMWR October 19, 2007
Notifiable Disease Data Team and 122 Cities Mortality Data Team
Patsy A. Hall
Deborah A. Adams Rosaline Dhara
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* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week
periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard
deviations of these 4-week totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of
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